Attorney Docket No.11676-003WO1 RNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF CROSS REFERENCE TO RELATED APPLICATIONS This PCT application claims priority to, and the benefit of, U.S. Provisional Patent Application No.63/403,914, filed September 6, 2022, which is incorporated by reference herein in its entirety. REFERENCE TO SEQUENCE LISTING The sequence listing submitted on September 6, 2023, as an .XML file entitled “11676- 003WO1_ST26.xml” created on September 5, 2023, and having a file size of 926,177 bytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5). FIELD The present disclosure relates to RNA sequences, compositions, and methods of use to prevent viral replication, prevent RNA polymerase activity, activate innate immune responses, or combinations thereof. BACKGROUND Influenza A viruses (IAV) are important human pathogens that generally cause a mild to moderately severe respiratory disease. A range of viral, host, and bacterial factors can influence the outcome of infections with IAV. One important factor is the activation of host protein retinoic acid-inducible gene I (RIG-I) by double-stranded 5ʹ di- or triphosphorylated RNA. Activated RIG- I translocates to mitochondria, and triggers oligomerization of mitochondrial antiviral signaling protein (MAVS) and subsequent phosphorylation of IRF3 and NF-kB, leading to the expression of innate immune genes, including interferon- ^ (IFN- ^) and IFN- ^. Innate immune gene expression typically leads to a protective antiviral state, but results in an overproduction of cytokines and chemokines when dysregulated. This phenomenon underlies the lethal pathology of infections with 1918 H1N1 pandemic or highly pathogenic avian IAV. Various viral and host factors have been implicated in causing immunopathology, including the products of aberrant viral replication. The emergence of viral and/or host factors that contribute to immunopathological events within the host, presents the need to develop compositions and methods to prevent viral functions and activate the host immune systems against viral pathogens. Attorney Docket No.11676-003WO1 The compositions and methods disclosed herein address these needs. SUMMARY The present disclosure provides ribonucleic acid (RNA) compositions and methods of use to prevent, reduce, and/or decrease viral replication, increase and/or activate an innate immune response, or a combination thereof to be used for treatment and/or prevention of an infection. In one aspect, disclosed herein is an engineered RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus. In some embodiments, the stem portion comprises at least 14 bps in length. In some embodiments, the target virus comprises a negative-sense RNA virus. In some embodiments, the negative-sense RNA virus comprises Influenza A virus (IAV), Ebola virus, Nipah virus, Hanta virus, Hendra virus, Lassa virus, or Rabies virus. In some embodiments, the RNA sequence comprises between about 40 to about 80 nucleotides. In some embodiments, the RNA sequence comprises at least 60% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 70% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 80% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 90% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises any one of sequences selected from SEQ ID NO: 4-30. In some embodiments, the footprint of the RNA polymerase comprises an area within the RNA polymerase capable of holding a designated number of nucleotides. In some embodiments, the designated number of nucleotides comprises about 20 nucleotides. In some embodiments, the 5’ promoter comprises about 12 nucleotides in length. In some embodiments, the 3’ promoter comprises about 13 nucleotides in length. In one aspect, disclosed herein is a cell expressing the engineered RNA of any preceding aspect. In one aspect, disclosed herein is a method of reducing viral replication, inducing activation of an innate immune response to a target virus, or a combination thereof, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein Attorney Docket No.11676-003WO1 the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and contacting the RNA sequence to the RNA polymerase of the target virus, wherein the RNA sequence forms a template loop (t-loop) around the RNA polymerase to reduce viral replication, and wherein the RNA sequence comprises an agonist to activate the innate immune response. In one aspect, disclosed herein is a method of preventing RNA polymerase activity, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 14 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and contacting the RNA sequence to the RNA polymerase of the target virus, wherein the RNA sequence forms a template loop (t-loop) around the RNA polymerase to stop RNA polymerase activity. In one aspect, disclosed herein is a method of treating and/or preventing a viral infection, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and administering the RNA sequence to a subject, wherein the RNA sequence contacts the RNA polymerase of the target virus, and wherein the RNA sequence reduces viral replication and/or activates the innate immune response in the subject relative to an untreated control subject. In one aspect, disclosed herein is a method of performing a template loop (t-loop) analysis, the method comprising identifying a template loop RNA sequence, blocking off a portion of the template loop RNA sequence to represent a footprint of a virus RNA polymerase, determining a t- loop ΔG, an upstream ΔG for a stretch of 10 nucleotides of the footprint, and a downstream ΔG for a stretch of 10 nucleotides of the footprint, and determining a ΔΔG for a likelihood of t-loop formation by subtracting the upstream ΔG and downstream ΔG from the t-loop ΔG, and moving the footprint in a one-nucleotide increment along the template loop RNA sequence, and repeating step c) until the ΔΔG values have been determined for an entire template loop RNA sequence. In some embodiments, the stem portion comprises at least 14 bps in length. In some embodiments, the target virus comprises a negative-sense RNA virus. In some embodiments, the negative-sense RNA virus comprises Influenza A virus (IAV), Ebola virus, Nipah virus, Hanta virus, Hendra virus, Lassa virus, or Rabies virus. Attorney Docket No.11676-003WO1 In some embodiments, the RNA sequence comprises between about 40 to about 80 nucleotides. In some embodiments, the RNA sequence comprises any one of sequences selected from SEQ ID NO: 4-30. In some embodiments, the footprint of the RNA polymerase comprises an area within the RNA polymerase capable of holding a designated number of nucleotides. In some embodiments, the designated number of nucleotides comprises about 20 nucleotides. In some embodiments, the 5’ promoter comprises about 12 nucleotides in length. In some embodiments, the 3’ promoter comprises about 13 nucleotides in length. In some embodiments, the stem-loop inhibits the RNA polymerase from replicating a genome of the target virus. In some embodiments, the RNA sequence forms a template loop (t-loop) around the RNA polymerase to reduce viral replication. In some embodiments, the innate immune response comprises binding a host pathogen receptor to the RNA sequence. In some embodiments, the host pathogen receptor comprises a retinoic acid-inducible gene I (RIG-I). In one aspect, disclosed herein is a non-transitory computer-readable storage medium comprising instructions that, when executed, cause at least one processor to perform the method of any preceding aspect. In one aspect, disclosed herein is a computer-implemented method for generating at least one optimal ribonucleic acid (RNA) sequence for reducing viral replication and/or inducing activation of an innate response to a target virus, the computer-implemented method comprising retrieving, by one or more processors, an RNA polymerase of the target virus, performing, by the one or more processors, a template loop (t-loop) analysis operation on the RNA polymerase, determining, by the one or more processors, at least one optimal RNA sequence corresponding with the RNA polymerase of the target virus based on results of the t-loop analysis operation, and outputting, by the one or more processors, a ΔG, a location of the ΔG, a t-loop structure, or combinations thereof. In some embodiments, the output comprises the at least one optimal RNA sequence. In some embodiments, the computer-implemented method further comprises receiving, by the one or more processors, one or more user-defined parameters associated with the RNA polymerase of the target virus, and performing, by the one or more processors, the t-loop analysis operation based at least on the one or more user-defined parameters. In some embodiments, the t-loop analysis operation is used interchangeably with a sliding window operation. In some embodiments, the computer-implemented method further comprises determining, by the one or more processors, at least one criterion of a composition for administration to a subject based on the at least one optimal RNA sequence. Attorney Docket No.11676-003WO1 BRIEF DESCRIPTION OF FIGURES The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects described below. FIGS.1A, 1B, 1C, and 1D show the sequence-dependent reduction of mvRNA replication and induction of IFN- ^ promoter activation. FIG. 1A shows the schematic of mvRNA formation via intramolecular template switching. This process has the potential to create novel RNA structures. Produced mvRNAs are bound by RIG-I, leading to the expression of innate immune responses. FIG. 1B shows the IFN- ^ promoter activation following transfection of in vitro transcribed segment 5 mvRNAs of 47 or 76 nt in length. FIG.1C shows the replication of model mvRNAs in HEK 293T cells by the influenza virus A/WSN/33 (H1N1) RNA polymerase. RNA levels were analyzed by primer extension and the ability of mvRNA replication to induce IFN- ^ promoter activity was analyzed using a luciferase-based IFN- ^ reporter assay. Non-specific primer extension signals in FIG.1C are indicated with *. FIG.1D shows the RT-qPCR analysis of IFN- ^ mRNA levels. Data from three biological repeats are shown. FIGS.2A, 2B, and 2C show that t-loops induce RNA polymerase stalling. FIG. 2A shows the schematic of RNA structure formation upstream, around (t-loop), and downstream of the RNA polymerase. FIG.2B shows the ΔG values for RNA structures forming upstream (green), around (t-loop; orange) or downstream (purple) of the RNA polymerase were computed using a sliding window approach. The difference in ΔG (ΔΔG) between the formation of a t-loop and structures forming upstream or downstream the RNA polymerase was computed and shown in the bottom graph. Heatmap shows zoom in on ΔΔG values computed for middle of the mvRNA templates used. FIG. 2C shows the replication of the NP71.1, NP71.2 or the destabilized NP71.6 mvRNA templates in HEK 293T cells by the WSN RNA polymerase. RNA levels were analyzed by primer extension and the ability of mvRNA replication to induce IFN promoter activity was analyzed using a luciferase reporter assay. Non-specific primer extension signals in FIG. 2C are indicated with *. Data from three biological repeats are shown. FIGS.3A, 3B, and 3C show that mvRNA t-loops stall RNA polymerase activity and induce IFN- ^ promoter activation. FIG. 3A shows the heat map showing ΔΔG as estimate for the likelihood of t-loop formation. FIG. 3B shows the replication of mvRNA templates. Top panel shows primer extension analysis. Graphs show quantification of template loop RNA level and IFN- ^ promoter activation. Data from three biological repeats are shown. FIG.3C shows the analysis of IAV RNA polymerase activity in vitro. Attorney Docket No.11676-003WO1 FIGS.4A, 4B, 4C, 4D, and 4E show the mutation near template exit channel increases RNA polymerase sensitivity to t-loops. FIG. 4A shows the structure of the pre-termination complex of the bat influenza A virus RNA polymerase (PDB 6SZU). The 5ʹ and 3ʹ ends of the template are shown in black and gold, respectively. The body of the template is shown in dark blue and the nascent RNA in red. Location of PB1 K669 and PB2 T81 are indicated. FIG.4B shows the amino acid alignment of PB1 C-terminus. PB1 K669 is indicated with an arrow. FIG.4C shows the IFN- ^ promoter activity and segment 6 viral RNA levels in the presence of wildtype and K669A RNA polymerases. For the segment 6 vRNA template, the mRNA, cRNA and vRNA species are indicated. 5S rRNA and western blot for PB1 subunit expression are shown as loading control. FIGS. 4D and 4E show the IFN- ^ promoter activity and mvRNA template levels for five NP71 mvRNA templates in the presence of wildtype and K669A RNA polymerases. RNA levels were analyzed by primer extension. 5S rRNA and western blot for PB1 subunit, NP, and tubulin expression are shown as loading control. Data from three biological repeats are shown. FIGS. 5A, 5B, 5C, 5D, 5E, 5F, and 5G show the reduced mvRNA replication in viral infections is correlated with IFN- ^ promoter activation. FIGS. 5A and 5B show the number of mvRNA copies per unique mvRNA sequence detected in ferret lungs infected with BM18 or A549 cells infected with WSN. In each graph two biological repeats are shown. FIG.5C shows the ΔΔG heat map of negative sense template of WSN segment 2 derived mvRNAs. Half of the mvRNA template is indicated with a dotted line. FIG. 5D shows the replication of segment 2-derived mvRNAs identified by NGS in HEK 293T cells by the WSN RNA polymerase. RNA levels were analyzed by primer extension. The ability of mvRNA replication to induce IFN- ^ promoter activity was analyzed using a luciferase reporter assay. Asterisk (*) indicates non-specific radioactive signal. Data from four biological repeats are shown. FIG. 5E shows the IFN- ^ induction is negatively correlated with template replication level. PB1-mvRNA G and I were excluded from the fit to the exponential decay because they are shorter than the IFN- ^ promoter induction cut-off of 56 nt. FIG. 5F shows the IFN- ^ induction is negatively correlated with ΔΔG of first half of template mvRNA. FIG. 5G shows the schematic of aberrant RNA synthesis by the IAV RNA polymerase. T-loops present in some mvRNAs lead to reduced RNA polymerase processivity. This may induce template release and/or binding of the mvRNA template to RIG-I. Host factor ANP32A, which plays a key role during cRNA and vRNA synthesis, is not shown for clarity. FIGS. 6A, 6B, 6C, and 6D show the effect of a single spinach aptamer on mvRNA replication. FIG. 6A shows how to rule out that a single RNA structure upstream of the RNA polymerase reduces activity, the NP56 mvRNA template was engineered and the RNA aptamer Spinach was inserted, creating NP56-S1. FIG.6B shows a Spinach-containing mvRNAs generated Attorney Docket No.11676-003WO1 in vitro demonstrated fluorescence after addition of DFHBI relative to the 56-nt control mvRNA, confirming that the aptamer folds properly in the context of the IAV promoter sequence. FIG.6C shows the TIRF microscopy image of a 56-nt mvRNA or Spinach-containing mvRNA generated in vitro in the presence of DFHBI. FIG. 6D show the after transfection of plasmids encoding the Spinach-containing mvRNA NP56-S1 into HEK293T cells and analysis of the RNA produced using primer extension, no difference in replication was observed relative to our NP56 control mvRNA. FIG. 7 shows the fractionation of HEK 293T cells transfected with IAV RNA polymerase and a 76 nt-long segment 5-derived mvRNA. Top panel shows primer extension analysis of RNA extracted from fractions. Bottom four panels show western blot analysis. For each lane, comparable amounts were loaded. FIGS.8A, 8B, and 8C show the aberrant RNA sequences, effect of exogenous mvRNAs on infection, and re-transfection of total RNA. FIG.8A shows the alignment of aberrant RNA products isolated from in vitro replication assays. FIG.8B shows the IFN- ^ promoter activity induced by the re-transfection of total RNA isolated from HEK 293T cells transfected with plasmids expressing segment 5-derived mvRNAs and the viral RNA polymerase subunits. Luciferase signal was normalized to the NP47 mvRNA, which does not trigger innate immune responses. FIG.8C shows the induction of IRF3 phosphorylation by pre-transfected, exogenous mvRNAs during infection with IAV A/WSN/33 (H1N1). mvRNA amplification could not be detected by primer extension, likely because exogenous templates poorly compete with endogenous viral RNAs for replication. FIGS. 9A, 9B, and 9C show the characterization of MAVS ^-/- HEK 293 cells and mvRNA replication in MAVS ^-/- HEK 293 cells. FIG. 9A shows the western blot analysis of MAVS expression in wildtype or MAVS ^-/- HEK 293 cells. FIG. 9B shows the IFN- ^ promoter activity in wildtype or MAVS ^-/- HEK 293 cells following transfection of a plasmid expressing MAVS-flag. Bottom panel shows western blot of MAVS-flag expression. FIG. 9C shows the IFN- ^ promoter activity of HEK 293 MAVS ^-/- cells expressing mvRNAs NP71.1-NP71.5. and primer extension analysis of mvRNA NP71.1-NP71.5 replication in HEK 293 MAVS ^-/- cells. P-values were computed using student t-test. FIG.10 shows the replication of model mvRNAs in HEK 293T cells by the IAV A/Brevig Mission/1/18 (BM18) or A/duck/Fujian/01/02 (FJ02) RNA polymerases. The ability of these reactions to induce IFN- ^ promoter activity was analyzed using a luciferase reporter assay. FIGS.11A, 11B, 11C, 11D, and 11E show the sliding-window analysis of the free energy (ΔG) of transient secondary RNA structure formation near the IAV RNA polymerase. FIG. 11A shows how to calculate the ΔG for a t-loop, 10 nt on either side of the polymerase were allowed Attorney Docket No.11676-003WO1 to fold using the duplex-fold algorithm of the ViennaRNA package. To calculate the ΔG for alternative structures, co-fold of the ViennaRNA package was used. The ΔΔG for the likelihood of t-loop formation was calculated by subtracting the upstream and downstream ΔG values from the t-loop ΔG value. FIG.11B shows an example of Python script output (“&” represents the loop structure). FIG.11C shows the ΔΔG values for positive sense 71-nt long mvRNA templates. FIG. 11D shows the ΔΔG values for negative sense 71-nt long mvRNA templates. FIG.11E shows the t-loop ΔG values for positive sense and negative sense NP47, NP56 and NP76 mvRNA templates. FIGS. 12A, 12B, 12C, and 12D show the replication of engineered mvRNAs and their ability to induce IFN- ^ promoter activity. FIG. 12A shows the alignment of t-loops (shaded orange) in NP71 mvRNA templates. Location of RNA polymerase entry (En) and exit (Ex) channel is shaded gray. FIG.12B shows the primer extension analysis of RNA extracted from HEK 293T cells expressing NP71 mvRNA templates. FIG. 12C shows the alignment of t-loops (shaded orange) of additional NP71 mvRNA templates. The location of RNA polymerase entry and exit channel is shaded gray. FIG. 12D shows the primer extension analysis of RNA extracted from HEK 293T cells expressing NP71 mvRNA templates. Second and third panels show western blot analysis. Top graph shows quantification of mvRNA template level, while bottom graph shows IFN- ^ promoter activity analysis using a luciferase reporter. FIGS. 13A and 13B show the analysis of IAV RNA polymerase template binding and release on different mvRNA templates in vitro. FIG.13A show the binding of radiolabeled RNA templates by mOrange-tagged, immobilized IAV RNA polymerase in the absence and presence of ApG and NTPs. FIG. 13B shows the binding of radiolabeled RNA products by mOrange-tagged, immobilized IAV RNA polymerase in the absence and presence of free inactive IAV RNA polymerase (PB1a). FIGS.14A and 14B show the selection of segment 2 mvRNAs. FIG.14A shows the segment 2 mvRNA sizes and abundance in three next generation sequencing experiments. FIG.14B shows the relation between mvRNA level in transfection assay and mvRNA read counts in next generation sequencing. The mvRNAs F, G and H are indicated. FIGS.15A and 15B show the relation between the mvRNA template length and the IFN- ^ promoter activity induction (FIG. 15A), or the mvRNA template length and mvRNA replication (FIG.15B). FIGS. 16A, 16B, and 16C show the segment 2 mvRNA replication in MAVS ^-/- HEK 293 cells. FIG. 16A shows the IFN- ^ promoter activity measured after re-transfection of total RNA extracted from HEK 293T cells expressing segment 2 mvRNAs into HEK 293T cells. FIG. 16b shows the IFN- ^ promoter activity induced by expression of segment 2 mvRNAs in MAVS ^-/- HEK Attorney Docket No.11676-003WO1 293 cells. FIG.16C shows the primer extension analysis of segment 2 mvRNAs levels in wildtype and MAVS ^-/- HEK 293 cells. P-values were computed using one-way ANOVA with multiple- corrections relative to template A or the empty plasmid control. FIG.17 shows the induction of IFN beta promoter activity by segment 3 and 4 mvRNAs. P- values were computed using one-way ANOVA with multiple-corrections relative to the NP71.1 mvRNA template. FIG.18 shows an example computing device. FIG. 19 shows a flowchart diagram of a computer-implemented method for generating at least one optimal RNA sequence for reducing viral replication and/or inducing activation of an innate response to a target virus in accordance with certain embodiments of the present disclosure. FIGS.20A and 20B show that the RIG-I helicase is required for mvRNA extraction. FIG.21 shows that mvRNAs are more potent in IFN activation. FIGS. 22A, 22B, and 22C show that RNA templates containing t-loops do not trigger template release in vitro. FIGS.23A and 23B show a radio-labeled product RNA binding assay and demonstrate that full length RNA is not released by the replication complex. DETAILED DESCRIPTION The following description of the disclosure is provided as an enabling teaching of the disclosure in its best, currently known embodiment(s). To this end, those skilled in the relevant art will recognize and appreciate that many changes can be made to the various embodiments of the invention described herein, while still obtaining the beneficial results of the present disclosure. It will also be apparent that some of the desired benefits of the present disclosure can be obtained by selecting some of the features of the present disclosure without utilizing other features. Accordingly, those who work in the art will recognize that many modifications and adaptations to the present disclosure are possible and can even be desirable in certain circumstances and are a part of the present disclosure. Thus, the following description is provided as illustrative of the principles of the present disclosure and not in limitation thereof. Reference will now be made in detail to the embodiments of the invention, examples of which are illustrated in the drawings and the examples. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Attorney Docket No.11676-003WO1 Terminology Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments and are also disclosed. As used in this disclosure and in the appended claims, the singular forms “a”, “an”, “the”, include plural referents unless the context clearly dictates otherwise. The following definitions are provided for the full understanding of terms used in this specification. The terms "about" and "approximately" are defined as being “close to” as understood by one of ordinary skill in the art. In one non-limiting embodiment the terms are defined to be within 10%. In another non-limiting embodiment, the terms are defined to be within 5%. In still another non- limiting embodiment, the terms are defined to be within 1%. Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed the “less than or equal to 10”as well as “greater than or equal to 10” is also disclosed. It is also understood that throughout the application, data is provided in a number of different formats, and that this data represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit Attorney Docket No.11676-003WO1 between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed. As used herein, the terms "may," "optionally," and "may optionally" are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation "may include an excipient" is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient. "Comprising" is intended to mean that the compositions, methods, etc. include the recited elements, but do not exclude others. "Consisting essentially of'' when used to define compositions and methods, shall mean including the recited elements, but excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of'' shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions provided and/or claimed in this disclosure. Embodiments defined by each of these transition terms are within the scope of this disclosure. An "increase" can refer to any change that results in a greater amount of a symptom, disease, composition, condition, or activity. An increase can be any individual, median, or average increase in a condition, symptom, activity, composition in a statistically significant amount. Thus, the increase can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% or more increase so long as the increase is statistically significant. A "decrease" can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity. A substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance. Also, for example, a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed. A decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount. Thus, the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% decrease so long as the decrease is statistically significant. "Inhibit," "inhibiting," and "inhibition" mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the Attorney Docket No.11676-003WO1 reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. By “reduce” or other forms of the word, such as “reducing” or “reduction,” means lowering of an event or characteristic (e.g., viral replication or viral infection). It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces viral infection” or “reduces viral replication” means reducing the rate viral infection or rate of viral replication relative to a standard or a control. By “prevent” or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed. The terms “treat,” “treating,” and grammatical variations thereof as used herein, include partially or completely delaying, alleviating, mitigating or reducing the intensity of one or more attendant symptoms of a disorder or condition and/or alleviating, mitigating or impeding one or more causes of a disorder or condition. Treatments according to the disclosure may be applied preventively, prophylactically, palliatively or remedially. Treatments are administered to a subject prior to onset (e.g., before obvious signs of infection), during early onset (e.g., upon initial signs and symptoms of infection), or after an established development of infection. The term “subject” refers to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. In one aspect, the subject can be human, non-human primate, bovine, equine, porcine, canine, or feline. The subject can also be a guinea pig, rat, hamster, rabbit, mouse, or mole. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician. A "promoter," as used herein, refers to a sequence in DNA that mediates the initiation of transcription by an RNA polymerase. Transcriptional promoters may comprise one or more of a number of different sequence elements as follows: 1) sequence elements present at the site of transcription initiation; 2) sequence elements present upstream of the transcription initiation site and; 3) sequence elements down- stream of the transcription initiation site. The individual Attorney Docket No.11676-003WO1 sequence elements function as sites on the DNA, where RNA polymerases and transcription factors facilitate positioning of RNA polymerases on the DNA bind. “Expression” as used herein refers to the process by which information from a gene is used in the synthesis of a functional gene product that enables it to produce a peptide/protein end product, and ultimately affect a phenotype, as the final effect. As used herein, the term “polymerase” refers to an enzyme that synthesizes long chains of polymers or nucleic acids. RNA polymerases are used to assemble RNA molecules, respectively, by copying a nucleic acid template strand using base-pairing interactions. The term “administer,” “administering”, or derivatives thereof refer to delivering a composition, substance, inhibitor, or medication to a subject or object by one or more the following routes: oral, topical, intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra- joint, parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation or via an implanted reservoir. The term “parenteral” includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injections or infusion techniques. “Composition” refers to any agent that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, e.g., treatment of a disease or other undesirable physiological condition, and prophylactic effects, e.g., prevention of a disease or other undesirable physiological condition (including, but not limited to Influenza). The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, a vector, polynucleotide, cells, salts, esters, amides, proagents, active metabolites, isomers, fragments, analogs, and the like. When the term “composition” is used, then, or when a particular composition is specifically identified, it is to be understood that the term includes the composition per se as well as pharmaceutically acceptable, pharmacologically active vector, polynucleotide, salts, esters, amides, proagents, conjugates, active metabolites, isomers, fragments, analogs, etc. In some aspects, the composition disclosed herein comprises an engineered RNA sequence and a pharmaceutically effective carrier. "Pharmaceutically acceptable carrier" (sometimes referred to as a “carrier”) means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic, and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use. The terms "carrier" or "pharmaceutically acceptable carrier" can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents. Attorney Docket No.11676-003WO1 As used herein, the term “carrier” encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations. The choice of a carrier for use in a composition will depend upon the intended route of administration for the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 21st Edition, ed. University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia, PA, 2005. Examples of physiologically acceptable carriers include saline, glycerol, DMSO, buffers such as phosphate buffers, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN ^TM (ICI, Inc.; Bridgewater, New Jersey), polyethylene glycol (PEG), and PLURONICS ^TM (BASF; Florham Park, NJ). To provide for the administration of such dosages for the desired therapeutic treatment, compositions disclosed herein can advantageously comprise between about 0.1% and 99% by weight of the total of one or more of the subject compounds based on the weight of the total composition including carrier or diluent. A “nucleotide” is a compound consisting of a nucleoside, which consists of a nitrogenous base and a 5-carbon sugar, linked to a phosphate group forming the basic structural unit of nucleic acids, such as DNA or RNA. The four types of DNA nucleotides are adenine (A), cytosine (C), guanine (G), and thymine (T), each of which are bound together by a phosphodiester bond to form a nucleic acid molecule. A “nucleic acid” is a chemical compound that serves as the primary information-carrying molecules in cells and make up the cellular genetic material. Nucleic acids comprise nucleotides, which are the monomers made of a 5-carbon sugar (usually ribose or deoxyribose), a phosphate group, and a nitrogenous base. A nucleic acid can also be a deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA). A chimeric nucleic acid comprises two or more of the same kind of nucleic acid fused together to form one compound comprising genetic material. Herein the terms “nucleic acid” and “polynucleotide” are used interchangeably throughout the disclosure. The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore Attorney Docket No.11676-003WO1 achieve a more meaningful comparison of the two sequences. Percent identity for a nucleic acid sequence may be determined as understood in the art. (See, e.g., U.S. Pat. No. 7,396,664, which is incorporated herein by reference in its entirety). A suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403410), which is available from several sources, including the NCBI, Bethesda, Md., at its website. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at the NCBI website. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed above). Percent identity may be measured over the length of an entire defined polynucleotide sequence or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length may be used to describe a length over which percentage identity may be measured. A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence. A “variant,” “mutant,” or “derivative” of a particular nucleic acid sequence may be defined as a nucleic acid sequence having at least 50% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool available at the National Center for Biotechnology Information's website. (See Tatiana A. Tatusova, Thomas L. Madden (1999), “Blast 2 sequences—a new tool for comparing protein and nucleotide sequences”, FEMS Microbiol Lett. 174:247-250). In some embodiments a variant polynucleotide may show, for example, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length relative to a reference polynucleotide. A “genome” refers to a complete set of genes or genetic material present within a cell, tissue, or organism, including, but not limited to pathogenic genomes (i.e.: viral genomes). Attorney Docket No.11676-003WO1 Variants comprising a fragment of a reference nucleotide sequence are contemplated herein. A “fragment” is a portion of a nucleotide sequence which is identical in sequence to but shorter in length than the reference sequence. A fragment may comprise up to the entire length of the reference sequence, minus at least one nucleotide. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides of a reference polynucleotide. In some embodiments, a fragment may comprise at least 5, 10, 15, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 150, 250, or 500 contiguous nucleotides of a reference polynucleotide. Fragments may be preferentially selected from certain regions of a molecule, for example the 5′-terminal region and/or the 3′ terminal region of a polynucleotide. The term “at least a fragment” encompasses the full-length polynucleotide. A “host” refers to any animal (either vertebrate or invertebrate) or plant that harbors a smaller organism; whether their relationship is parasitic, pathogenic, or symbiotic, where the smaller organism generally uses the animal or plant for shelter and/or nourishment. The smaller organism can be a microorganism, such as bacteria, viruses, fungi, a parasite, including, but not limited to worms and insects. “Serotype” as used herein refers to a distinct variation within a species of bacteria or virus or among immune cells of different individuals. These microorganisms, viruses, or cells are classified together based on their surface antigens, allowing the epidemiologic classification of organisms to the subspecies level. As used herein, the term infection refers to the invasion of tissues by pathogens, their multiplication, and reaction of host tissues to the infectious agent and any toxins they release. Infections can be caused by a wide range of pathogen, most common are viruses. As used herein, “downstream” refers to the relative position of a genetic sequence, either DNA or RNA. Downstream relates to the 5’ to 3’ direction relative to the start site of transcription, wherein downstream is usually closer to the 3’ end of a genetic sequence. As used herein, “upstream” refers to the relative position of a genetic sequence, either DNA or RNA. Upstream relates to the 5’ to 3’ directions relative to the start site of transcription, wherein upstream is usually closer to the 5’ end of a genetic sequence. A “virus” is a microscopic infectious agent that replicates only inside the living cells of an organism. Viruses can infect all life forms, including mammalian and non-mammalian animals, plants, and other microorganisms. A complete virus, also known as a virion, consists of nucleic acid genetic material surrounded by a protective coat of protein called a capsid. Virus can have a lipid envelope derived from the infected host cell membrane. In general, there are five morphological virus types including helical, icosahedral, prolate, enveloped, and complex virus. A virus can either have a Attorney Docket No.11676-003WO1 DNA or RNA genome, though a vast majority have RNA genomes. Irrespective of the type of nucleic acid genome, a viral genome can be either a single-stranded genome or a double-stranded genome. RNA sequences and compositions RNA viruses are a group of viruses that have ribonucleic acid (RNA), in the form of single stranded RNA or double stranded RNA, as its genetic material. RNA viruses can be classified according to the polarity of the RNA into negative-sense RNA viruses or positive-sense RNA viruses. Viral RNA from a negative-sense RNA virus is complementary to messenger RNA (mRNA), and thus must be converted to positive-sense RNA by an RNA-dependent RNA polymerase before translation into viral proteins. Positive-sense viral RNA, on the other hand, is identical to mRNA, and can thus be translated immediately. RNA viruses generally comprise very high mutation rates because viral RNA polymerases lack the proofreading functions of DNA polymerases. This contributes to a genetic diversity of RNA molecules (viral RNA or vRNA) produced by RNA viruses. Viral RNA polymerases are also shown to generate aberrant RNA molecules called mini viral RNAs (mvRNAs) during replication of the viral genome. Given the genetic diversity of RNA viruses, there is a need to generate RNA sequences of compositions to prevent RNA virus replication in a host. In one aspect, disclosed herein is an engineered RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus. In one aspect, disclosed herein is an engineered RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of influenza A virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the influenza A virus. In some embodiments, the RNA sequences disclosed herein comprise or match a footprint of an RNA polymerase from a target virus. The footprint refers to an area or region within the RNA polymerase that encloses or surrounds an RNA molecule. The footprint also allows for a designated or optimal number of nucleotides to be held within the RNA polymerase. The footprint includes the entry and exit pathways for the RNA molecule to enter upon conversion to positive-sense RNA and exit after conversion to positive-sense RNA. Attorney Docket No.11676-003WO1 In some embodiments, the RNA sequences disclosed herein are suitable for RNA polymerases from a negative-sense RNA virus. The RNA sequences disclosed herein traps the viral replication complex (RNA polymerase) or competes with endogenous vRNAs to inhibit viral replication. The RNA sequences disclosed herein are potent inhibitors of viral infections including, but not limited to infections caused by influenza A virus, influenza B virus, influenza C virus, Ebola virus, Nipah virus, Hanta virus, Hendra virus, Lassa virus, or Rabies virus. Thus, such viruses are sensitive to template loops (t-loops) and are inhibited in similar manners. The RNA sequences disclosed herein can be coupled to a ubiquitin ligase recognition signal (e.g., PROTAC) and trigger the degradation of viral proteins by the proteasome. In some embodiments, the RNA sequences disclosed herein can activate the immune response upon viral infection and can induce a protective antiviral response. There are various previous methods on using defective interfering RNA viruses/particles, but these rely on using natural sequences. The sequences and the algorithm that are disclosed herein engineer viruses capable of inducing a protective response more robustly, for instance by inserting the sequences into the genome or creating viruses in which one of the viral genome segments is replaced with an RNA capable of trapping the viral replication complex. The RNA sequences disclosed herein can be added to live- attenuated vaccines and act as an adjuvant. In the vaccines, the RNA sequence(s) is bound by the live virus upon infection. After initial steps of infection, the RNA sequences limit viral replication and/or trigger a protective immune response. Said vaccines can be administered during an outbreak of a known or novel virus to provide subjects with a protective immune response before traditional or RNA vaccines are available. Said vaccine can also be administered to healthcare workers before exposure to viruses. In some embodiments, disclosed herein are RNA sequences used to inhibit influenza virus replication and trigger activation of the innate immune system while the RNA is bound by the viral replication complex (RNA polymerase). The template loop (t-loop) portion of the RNA sequence inhibits other negative viruses, not limited to influenza viruses. Thus, the RNA sequences disclosed herein inhibit viral RNA polymerase activity and/or viral replication in RNA viruses that are similar in size and work mechanistically in similar ways to influenza viruses and other negative-sense RNA viruses. Under appropriate parameters, the RNA sequence(s) hybridizes, or binds internally to form the t-loop. To reduce viral replication and induce activation of the innate immune response, the stem of the t-loop comprises at least 5 bp long. To prevent the activity of the RNA polymerase entirely, the stem comprises at least 14 bp long. The t-loop is flanked by the natural influenza A virus 5’ and 3’ promoter RNA sequences, which are 12 and 13 nt respectively. Attorney Docket No.11676-003WO1 In some embodiments, the RNA sequence can reduce or completely stop the activity of the RNA polymerase. In some embodiments, the stem portion comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 bps in length. In some embodiments, the loop portion comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides in length. In some embodiments, the target virus comprises a negative-sense RNA virus. In some embodiments, the negative-sense RNA virus comprises Influenza A virus (IAV), Ebola virus, Nipah virus, Hanta virus, Hendra virus, Lassa virus, or Rabies virus. It should be understood that negative- sense viruses can comprise multiple types of genomes ranging from a single RNA molecule up to eight segments of RNA polymers. For example, IAV and Influenza V virus (IBV) comprise eight segments, while Influenza C virus comprises seven segments. Thus, in some embodiments the engineered RNA sequence targets at least one single RNA molecule or targets up to 8 segments of RNA. In some embodiments, the RNA sequence comprises between about 40 to about 130 nucleotides. In some embodiments, the RNA sequence comprises between about 52 to about 71 nucleotides. In some embodiments, the RNA sequence comprises about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, or 130 nucleotides. It should be noted that the RNA sequences disclosed herein are shorter than defective interfering influenza virus RNAs (including, but not limited to defective interfering (DI) RNAs or DI viruses) described in the art. In some embodiments, the RNA sequence comprises at least 60% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 70% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 80% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 90% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 95% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises at least 99% sequence identity to any one of SEQ ID NO: 4-30. In some embodiments, the RNA sequence comprises any one of sequences selected from SEQ ID NO: 4-30. Attorney Docket No.11676-003WO1 In some embodiments, the RNA sequence comprises SEQ ID NO: 4, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 5, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 6, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 7, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 8, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 9, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 10, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 11, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 12, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 13, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 14, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 15, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 16, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 17, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 18, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 19, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 20, or a variant thereof. In some embodiments, the RNA sequence comprises at least 60% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 70% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 80% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 90% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 95% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 99% sequence identity to any one of SEQ ID NO: 13. In some embodiments, the RNA sequence comprises at least 60% sequence identity to any one of SEQ ID NO: 14. In some embodiments, the RNA sequence comprises at least 70% sequence identity to any one of SEQ ID NO: 14. In some embodiments, the RNA sequence comprises at least 80% sequence identity to any one of SEQ ID NO: 14. In some embodiments, the RNA sequence comprises at least 90% sequence identity to any one of SEQ ID NO: 14. In some embodiments, the RNA sequence comprises at least 95% sequence identity to any one of SEQ ID NO: 14. In some embodiments, the RNA sequence comprises at least 99% sequence identity to any one of SEQ ID NO: 14. Attorney Docket No.11676-003WO1 In some embodiments, the RNA sequence comprises SEQ ID NO: 21, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 22, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 23, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 24, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 25, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 26, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 27, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 28, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 29, or a variant thereof. In some embodiments, the RNA sequence comprises SEQ ID NO: 30, or a variant thereof. In some embodiments, the RNA sequence comprises at least 60% sequence identity to any one of SEQ ID NO: 25. In some embodiments, the RNA sequence comprises at least 70% sequence identity to any one of SEQ ID NO: 25. In some embodiments, the RNA sequence comprises at least 80% sequence identity to any one of SEQ ID NO: 25. In some embodiments, the RNA sequence comprises at least 90% sequence identity to any one of SEQ ID NO: 25. In some embodiments, the RNA sequence comprises at least 95% sequence identity to any one of SEQ ID NO: 25. In some embodiments, the RNA sequence comprises at least 99% sequence identity to any one of SEQ ID NO: 25. In some embodiments, SEQ ID NO: 1, SEQ ID NO: 2, and/or SEQ ID NO: 3 can be used as a control sequence (such as, for example a negative control or a positive control). In some embodiments, the footprint of the RNA polymerase comprises an area within the RNA polymerase capable of holding a designated number of nucleotides. In some embodiments, the designated number of nucleotides comprises about 20 nucleotides. In some embodiments, the designated number of nucleotides comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides. In some embodiments, the 5’ promoter comprises about 12 nucleotides in length. In some embodiments, the 5’ promoter comprises about 10, 11, 12, 13, 14, 15 nucleotides in length. In some embodiments, the 3’ promoter comprises about 13 nucleotides in length. In some embodiments, the 3’ promoter comprises about 10, 11, 12, 13, 14, 15 nucleotides in length. In one aspect, disclosed herein is a cell expressing the engineered RNA of any preceding aspect. In some embodiments, the cell expresses or comprises a vector encoding the engineered RNA. In some embodiments, the cell is a mammalian cell or a bacterial cell. It should be understood that any vector capable of stably expressing the engineered RNA sequences can be used. The word “vector” refers to any vehicle that carries a polynucleotide into a Attorney Docket No.11676-003WO1 cell for the expression of the polynucleotide in the cell. The vector may be, for example, a plasmid, a virus, a phage particle, or a nanoparticle. Once transformed or transduced into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself. In some embodiments, the vector comprises a nucleic construct containing a nucleotide sequence which is operably linked to a suitable control sequence capable of effecting the expression of the nucleic acid in a suitable host cell. Such control sequences can include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable RNA ribosome binding sites, and sequences which control the termination of transcription and translation. In some embodiments, the vector comprises a lipid nanoparticle. Lipid nanoparticles can be used to deliver engineered RNA sequences to a cell. In some embodiments, the RNA sequence can be introduced into a host cell through genetic modification. In some embodiments, the RNA sequence is introduced into a host cell by any DNA or RNA delivery technology known in the art, or combinations thereof. In some embodiments, the vector comprises a plasmid. In some embodiments, the vector comprises an RNA polymerase I (pol I) promoter. In some embodiments, the vector comprises flanking the RNA sequence with a hepatitis delta virus ribozyme sequence. A non-limiting example of expression of an IAV is described in Fodor et al. “Rescue of Influenza A Virus from Recombinant DNA”. Journal of Virology. Nov.1999 pg.9679-9682, which is incorporated herein in its entirety as a reference for its teaching of designing a vector (such as, for example a plasmid) comprising IAV genes and expressing said vector in cells. Methods of treating, preventing, reducing, and/or decreasing viral infections Viral replication refers to the formation process of biological viruses during an infection in host cells. Because viruses can only multiply within a living host cell, the host cell must supply the energy, replicative machinery, and the low molecular weight precursors for synthesis of viral proteins and nucleic acids. The process of viral replication occurs in seven stages, including: 1) Attachment, wherein the virus attaches to the cell membrane of the host cell and injects genetic material into the host to initiate infection; 2) Entry, wherein the host cell membrane invaginates, or internalizes, the virus particles; 3) Uncoating, wherein the enzymes from the host cell strips away the virus protein coat to expose viral genome; 4) Transcription, wherein viral RNA can be directly translated into viral protein (positive-sense RNA viruses), or must first be transcribed into positive-sense RNA before protein translation (negative-sense or DNA viruses); 5) Synthesis of viral components, wherein the components of the virus are manufactured using existing enzymes and organelles of the host; 6) Viral Attorney Docket No.11676-003WO1 assembly, wherein the newly synthesized genome and proteins are assembled into a new, active virus; and 7) Release, wherein the newly assembled viruses are released by sudden rupture of the host cell or gradual extrusion of viruses from the host cell. It should be noted that during step 4, negative-sense RNA polymerases can generate aberrant RNA sequences (vRNAs and/or mvRNAs). It has been contemplated that generation of mvRNAs trigger an innate immune response against viral infections. The innate immune response refers to the first line of defense against invading pathogens that includes immune systems cells and proteins that protect against pathogens that have entered the host body. “The innate and adaptive immune systems” is incorporate herein by reference, in its entirety, for the teachings of the components and functions of the innate immune system (InformedHealth.org. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. The innate and adaptive immune systems. Available from: www.ncbi.nlm.nih.gov/books/NBK279396). A non-limiting example of an innate immune response includes the retinoic acid-inducible gene I (RIG-I) that is an RNA sensor important for detecting viral infections. The RIG-I sensor is a host pathogen receptor that, upon binding a target RNA molecule, initiates a cascade of signaling pathways that leads to interferon (IFN) expression. This innate response causes release of IFN proteins that activate and allow communication between immune system cells to eradicate the infectious pathogen. The present disclosure provides methods that manipulate and/or optimize the above mentioned processes to prevent, reduce, and/or decrease viral replication; prevent, reduce, and/or decrease RNA polymerase activity; activate and/or increase an innate immune response; treat and/or prevent a viral infection; or any combinations thereof. In one aspect, disclosed herein is a method of reducing viral replication, inducing activation of an innate immune response to a target virus, or a combination thereof, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and contacting the RNA sequence to the RNA polymerase of the target virus, wherein the RNA sequence forms a template loop (t-loop) around the RNA polymerase to reduce viral replication, and wherein the RNA sequence comprises an agonist to activate the innate immune response. In one aspect, disclosed herein is a method of preventing RNA polymerase activity, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 14 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target Attorney Docket No.11676-003WO1 virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and contacting the RNA sequence to the RNA polymerase of the target virus, wherein the RNA sequence forms a template loop (t-loop) around the RNA polymerase to stop RNA polymerase activity. In one aspect, disclosed herein is a method of treating and/or preventing a viral infection, the method comprising engineering an RNA sequence comprising a stem-loop, wherein the stem-loop comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, wherein the loop portion matches a footprint of an RNA polymerase of a target virus, and wherein the stem loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus, and administering the RNA sequence to a subject, wherein the RNA sequence contacts the RNA polymerase of the target virus, and wherein the RNA sequence reduces viral replication and activates the innate immune response in the subject relative to an untreated control subject. Disclosed herein are methods to activate the innate immune response using RNA-based inhibition of influenza virus replication. In some embodiments, the method comprises a stem portion with 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 bps in length. In some embodiments, the method comprises a loop portion with about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides in length. In some embodiments, the method comprises an RNA sequence with between about 40 to about 80 nucleotides. In some embodiments, the method comprises an RNA sequence with between about 52 to about 71 nucleotides. In some embodiments, the method comprises an RNA sequence with about 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 nucleotides. In some embodiments, the target virus comprises a negative-sense RNA virus. In some embodiments, the negative-sense RNA virus comprises Influenza A virus (IAV), Ebola virus, Nipah virus, Hanta virus, Hendra virus, Lassa virus, or Rabies virus. In some embodiments, the method comprises any one of sequences selected from SEQ ID NO: 4-30. In some embodiments, the footprint of the RNA polymerase comprises an area within the RNA polymerase capable of holding a designated number of nucleotides. In some embodiments, the designated number of nucleotides comprises about 20 nucleotides. In some embodiments, the designated number of nucleotides comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides. Attorney Docket No.11676-003WO1 In some embodiments, the method comprises a 5’ promoter with about 12 nucleotides in length. In some embodiments, the method comprises a 5’ promoter with about 10, 11, 12, 13, 14, 15 nucleotides in length. In some embodiments, the method comprises a 3’ promoter with about 13 nucleotides in length. In some embodiments, the method comprises a 3’ promoter with about 10, 11, 12, 13, 14, 15 nucleotides in length. In some embodiments, the stem-loop inhibits the RNA polymerase from replicating a genome of the target virus. In some embodiments, the stem-loop inhibits the RNA polymerase from replicating negative-sense RNA. In some embodiments, the RNA sequence forms a template loop (t-loop) around the RNA polymerase to reduce viral replication. In some embodiments, the method inhibits transcription, synthesis, assembly, and/or release of viral components. In some embodiments, the innate immune response comprises binding a host pathogen receptor to the RNA sequence. In some embodiments, the host pathogen receptor comprises a retinoic acid-inducible gene I (RIG-I). In some embodiments, the method comprises expression and/or release of IFN proteins against the viral infection. Methods of performing analyses Template loop (t-loop) structures are RNA sequences that form a nucleic acid complex around an RNA polymerase to stall or prevent replication. Under optimized parameters, the t-loop can also initiate an innate immune response (such as, for example triggering a RIG-I RNA sensor). To optimally prevent RNA polymerase functions, such as, for example replication, the t-loop matches or comprises a footprint of the RNA polymerase from a target virus, such as, for example, influenza A virus. A matching footprint allows the RNA sequence to reside within the entry, exit, and interior channels of the RNA polymerase (See Figure 2A (2 ^nd image; T-loop RNA structure)). The t-loop structure forms around the RNA polymerase when the 3’ terminus of the RNA sequence (generally located at the exit channel of the RNA polymerase) can hybridize, or bind, to the upstream 5’ terminus of the RNA sequence (generally located at the entry channel of the RNA sequence). The hybridizing, or binding, of the 3’ terminus to the 5’ terminus causes the internal nucleotides of the RNA sequence to loop around and through the RNA polymerase. The formation of at least one t-loop around an RNA polymerase can stall the RNA polymerase from replicating the viral genome. It should be understood that RNA sequence can form 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more t-loops around and through the RNA polymerase. Depending on the purpose of the RNA sequence (inhibition, innate immune activation, or both), the stem of a template loop (t-loop) can be modified, and the overall length of the RNA sequence optimized. Since the mechanism of action of t-loops is well-defined, an algorithm was Attorney Docket No.11676-003WO1 designed to evaluate and optimize the sequences in silico. Additional t-loop sequences, aside from those sequences disclosed herein, can be quickly identified using the in silico analyses disclosed herein. The specific parameters can be defined to broadly claim the whole RNA sequence space that yields t-loop sequences with similar properties. Thus, the present disclosure provides methods of analyzing t-loop sequences for use in inhibiting RNA polymerase activity, inhibiting viral replication, activating an innate immune response, or combinations thereof. In some embodiments, the analysis includes detecting or identifying the free energy of the t- loop, the upstream sequence, and downstream sequence of an RNA sequence template. In some embodiments, the analysis includes determining the differences in free energies between the t-loop, the upstream sequence, and the downstream sequence of the RNA sequence template. Free energy, also referred to as ΔG, refers to a thermodynamic property that defines an energy property or function of a system in thermodynamic equilibrium. Free energy has the dimensions of energy, and its value is determined by the state of the system. Free energy is used to determine how systems change and how much work (in the form of energy) they can produce. When referring to nucleic acid systems, nucleic acid free energy refers to how external and internal factors (such as, for example temperature, the number of nucleotides, and/or the type of nucleotides) affect the formation and/or binding of secondary or tertiary nucleic acid structures (including, but not limited to hairpins, stem loops, and/or t-loops). Detection of a ΔG for a given RNA sequence template informs on the parameters needed to optimally form a t-loop structure. Such parameters include, but are not limited to the appropriate temperature, the optimal number of nucleotides, and/or the optimal positioning of adenine, thymine, cytosine, and guanine nucleotides for hybridization of the RNA sequence template. In some embodiments, the temperature parameter for forming t-loops ranges from about 35°C to about 40°C. In some embodiments, the temperature parameter for forming t-loops ranges from about 36°C to about 38°C. In some embodiments, the temperature parameter for forming t-loops comprises about 37°C. In some embodiments, the temperature parameter for forming t-loops comprises about 36.0°C, 36.1°C, 36.2°C, 36.3°C, 36.4°C, 36.5°C, 36.6°C, 36.7°C, 36.8°C, 36.9°C, 37.0°C, 37.1°C, 37.2°C, 37.3°C, 37.4°C, 37.5°C, 37.6°C, 37.7°C, 37.8°C, 37.9°C, 38.0°C, 38.1°C, 38.2°C, 38.3°C, 38.4°C, 38.5°C, 38.6°C, 38.7°C, 38.8°C, 38.9°C, or 39.0°C. Additional optimization is required by determining the differences in free energies (ΔΔG) between the ΔG of the t-loop, ΔG of the upstream (5’) terminus sequence, and ΔG of the downstream (3’) terminus sequence (or promoters) of the RNA sequence template. Determining the ΔΔG can be repeat as many times as necessary until the ΔΔG values have been determined for an entire template loop RNA sequence. Attorney Docket No.11676-003WO1 In one aspect, disclosed herein is a method of performing a t-loop analysis, the method comprising identifying a template loop RNA sequence, blocking off a portion of the template loop RNA sequence to represent a footprint of a virus RNA polymerase, determining a t-loop ΔG, an upstream ΔG for a stretch of at 10 nucleotides of the footprint, and a downstream ΔG for a stretch of at 10 nucleotides of the footprint, and determining a ΔΔG for a likelihood of t-loop formation by subtracting the upstream ΔG and downstream ΔG from the t-loop ΔG, and moving the footprint in a one-nucleotide increment along the template loop RNA sequence, and repeating the previous step until the ΔΔG values have been determined for an entire template loop RNA sequence. In one aspect, disclosed herein is a method of designing single stranded RNA molecules that regulate viral replication and stimulate activation of the innate immune response leading to the production of interferons. In some embodiments, the method regulates influenza A viral replication. In some embodiments, the stretch of nucleotides comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides of the footprint. Computing Devices and Methods of Use Disclosed herein is an algorithm (Python code) to test the design of new RNA sequences in silico. It should be appreciated that the logical operations described herein with respect to the various figures may be implemented (1) as a sequence of computer-implemented acts or program modules (i.e., software) running on a computing device (e.g., the computing device described in Figure 18), (2) as interconnected machine logic circuits or circuit modules (i.e., hardware) within the computing device and/or (3) a combination of software and hardware of the computing device. Thus, the logical operations discussed herein are not limited to any specific combination of hardware and software. The implementation is a matter of choice dependent on the performance and other requirements of the computing device. Accordingly, the logical operations described herein are referred to variously as operations, structural devices, acts, or modules. These operations, structural devices, acts and modules may be implemented in software, in firmware, in special-purpose digital logic, and any combination thereof. It should also be appreciated that more or fewer operations may be performed than shown in the figures and described herein. These operations may also be performed in a different order than those described herein. Referring to Figure 18, an example computing device 1800 upon which embodiments of the invention may be implemented is illustrated. It should be understood that the example computing device 1800 is only one example of a suitable computing environment upon which embodiments of the invention may be implemented. Optionally, the computing device 1800 can be a well-known Attorney Docket No.11676-003WO1 computing system including, but not limited to, personal computers, servers, handheld or laptop devices, multiprocessor systems, microprocessor-based systems, personal network computers (PCs), minicomputers, mainframe computers, embedded systems, and/or distributed computing environments including a plurality of any of the above systems or devices. Distributed computing environments enable remote computing devices, which are connected to a communication network or other data transmission medium, to perform various tasks. In the distributed computing environment, the program modules, applications, and other data may be stored on local and/or remote computer storage media. In its most basic configuration, the computing device 1800 typically includes at least one processing unit 1806 and system memory 1804. Depending on the exact configuration and type of computing device, system memory 1804 may be volatile (such as random-access memory (RAM)), non-volatile (such as read-only memory (ROM), flash memory, etc.), or some combination of the two. This most basic configuration is illustrated in Figure 18 by the dashed line 1802. The processing unit 1806 may be a standard programmable processor that performs arithmetic and logic operations necessary for the operation of the computing device 1800. The computing device 1800 may also include a bus or other communication mechanism for communicating information among various components of the computing device 1800. Computing device 1800 may have additional features/functionality. For example, the computing device 1800 may include additional storage such as removable storage 1808 and non- removable storage 1810 including, but not limited to magnetic or optical disks or tapes. Computing device 1800 may also contain network connection(s) 1816 that allow the device to communicate with other devices. Computing device 1800 may also have input device(s) 1814 such as a keyboard, mouse, touch screen, etc. Output device(s) 1812, such as a display, speakers, printer, etc., may also be included. The additional devices may be connected to the bus in order to facilitate communication of data among the components of the computing device 1800. All these devices are well-known in the art and need not be discussed at length here. The processing unit 1806 may be configured to execute program code encoded in tangible, computer-readable media. Tangible, computer-readable media refers to any media that is capable of providing data that causes the computing device 1800 (i.e., a machine) to operate in a particular fashion. Various computer-readable media may be utilized to provide instructions to the processing unit 1806 for execution. Example of tangible, computer-readable media may include but is not limited to, volatile media, non-volatile media, removable media and non-removable media implemented in any method or technology for storage of information such as computer-readable instructions, data structures, program modules or other data. System Memory 1804, removable storage 1808, and non- Attorney Docket No.11676-003WO1 removable Storage 1810 are all examples of tangible computer storage media. Examples of tangible, computer-readable recording media include but are not limited to, an integrated circuit (e.g., field- programmable gate array or application-specific IC), a hard disk, an optical disk, a magneto-optical disk, a floppy disk, a magnetic tape, a holographic storage medium, a solid-state device, RAM, ROM, electrically erasable program read-only memory (EEPROM), flash memory or other memory technology, CD-ROM, digital versatile disks (DVD) or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices. In an example implementation, the processing unit 1806 may execute program code stored in the system memory 1804. For example, the bus may carry data to the system memory 1804, from which the processing unit 1806 receives and executes instructions. The data received by the system memory 1804 may optionally be stored on the removable storage 1808 or the non-removable storage 1810 before or after execution by the processing unit 1806. It should be understood that the various techniques described herein may be implemented in connection with hardware or software or, where appropriate, with a combination thereof. Thus, the methods and apparatuses of the presently disclosed subject matter, or certain aspects or portions thereof, may take the form of program code (i.e., instructions) embodied in tangible media, such as floppy diskettes, CD-ROMs, hard drives, or any other machine-readable storage medium wherein, when the program code is loaded into and executed by a machine, such as a computing device, the machine becomes an apparatus for practicing the presently disclosed subject matter. In the case of program code execution on programmable computers, the computing device generally includes a processor, a storage medium readable by the processor (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. One or more programs may implement or utilize the processes described in connection with the presently disclosed subject matter, for example, through the use of an application programming interface (API), reusable controls, or the like. Such programs may be implemented in a high-level procedural or object-oriented programming language to communicate with a computer system. However, the program(s) can be implemented in assembly or machine language if desired. In any case, the language may be a compiled or interpreted language, and it may be combined with hardware implementations. In one aspect, disclosed herein is a non-transitory computer-readable storage medium comprising instructions that, when executed, cause at least one processor to perform the method of any preceding aspect. In some implementations, the techniques described herein relate to a computer-implemented method for generating at least one optimal RNA sequence for reducing viral replication and/or inducing activation of an innate response to a target virus, the computer-implemented method Attorney Docket No.11676-003WO1 including: retrieving, by one or more processors, an RNA polymerase of the target virus; performing, by the one or more processors, a template loop (t-loop) analysis operation on the RNA polymerase; determining, by the one or more processors and based on results from the t-loop analysis operation and/or sliding window operation, at least one optimal RNA sequence corresponding with the RNA polymerase of the target virus; and outputting, by the one or more processors, the at least one optimal RNA sequence (e.g., via a display device or other output device). In some implementations, the techniques described herein relate to a computer-implemented method, further including receiving, by the one or more processors, one or more user-defined parameters associated with the RNA polymerase of the target virus; and performing, by the one or more processors, the t-loop analysis operation based at least on the one or more user-defined parameters. In some implementations, the techniques described herein relate to a computer-implemented method, further including determining, by the one or more processors, at least one criterion of a composition for administration to a subject based on the at least one optimal RNA sequence. Figure 19 is a flowchart of an example computer-implemented method 1900 for generating at least one optimal RNA sequence for reducing viral replication and/or inducing activation of an innate response to a target virus. In some implementations, the method 1900 can be performed by a processing circuitry (for example, but not limited to, an application-specific integrated circuit (ASIC), or a central processing unit (CPU)). In some examples, the processing circuitry may be electrically coupled to and/or in electronic communication with other circuitries of an example computing device, such as, but not limited to, the example computing device 1800 described above in connection with Figure 18. In some examples, embodiments may take the form of a computer program product on a non-transitory computer-readable storage medium storing computer-readable program instruction (e.g., computer software). Any suitable computer-readable storage medium may be utilized, including non-transitory hard disks, CD-ROMs, flash memory, optical storage devices, or magnetic storage devices. At step/operation 1910, at least one processor (such as, but not limited to, at least one processor or processing circuitry of the computing device 1800) retrieves an RNA polymerase of the target virus. In some implementations, at step/operation 1910, the at least one processor retrieves/receives one or more user-defined parameters associated with the RNA polymerase of the target virus. At step/operation 1912, the at least one processor performs a template loop (t-loop) analysis operation on the RNA polymerase. In some implementations, the at least one processor performs the t-loop analysis operation based at least in part on the retrieved/received one or more user-defined Attorney Docket No.11676-003WO1 parameters. In some embodiments, the t-loop analysis operation comprises a sliding window operation as described in more detail herein. Example 6 below provides an example algorithm (Python script) for performing a t-loop analysis operation/sliding window operation in accordance with embodiments of the present disclosure. At step/operation 1914, the at least one processor determines at least one optimal RNA sequence corresponding with the RNA polymerase of the target virus based on results (e.g., one or more determined values) from the t-loop analysis operation. In some embodiments, the at least one optimal RNA sequence comprises a stem-loop. In some examples, the stem-loop further comprises a stem portion with at least 5 base pairs (bps) in length and a loop portion with about 20 nucleotides in length, and wherein the loop portion matches a footprint of the RNA polymerase of the target virus. In some examples, the stem-loop is flanked by a 5’ promoter and a 3’ promoter RNA sequence of the target virus. At step/operation 1916, the at least one processor outputs (e.g., via a display device) the at least one optimal RNA sequence. For example, the processor may output user-interface data to an end user via a graphical user interface or generate and provide (e.g., send, transmit) a text file. Additionally, and/or alternatively, the at least one processor can output at least one criterion of a composition (or instructions for engineering the composition) for administration to a subject based on the at least one optimal RNA sequence. In one aspect, disclosed herein is a computer-implemented method for generating at least one optimal ribonucleic acid (RNA) sequence for reducing viral replication and/or inducing activation of an innate response to a target virus, the computer-implemented method comprising retrieving, by one or more processors, an RNA polymerase of the target virus, performing, by the one or more processors, a template loop (t-loop) analysis operation on the RNA polymerase, determining, by the one or more processors, at least one optimal RNA sequence corresponding with the RNA polymerase of the target virus based on results of the t-loop analysis operation, and outputting, by the one or more processors, a ΔG, a location of the ΔG, a t-loop structure, or combinations thereof. In some embodiments, the output comprises the at least one optimal RNA sequence. In some embodiments, the computer-implemented method further comprises receiving, by the one or more processors, one or more user-defined parameters associated with the RNA polymerase of the target virus, and performing, by the one or more processors, the t-loop analysis operation based at least on the one or more user-defined parameters. In some embodiments, the t-loop analysis operation is used interchangeably with a sliding window operation. In some embodiments, the computer-implemented method further comprises determining, by the one or more processors, at least Attorney Docket No.11676-003WO1 one criterion of a composition for administration to a subject based on the at least one optimal RNA sequence. In some embodiments, the method can be used to optimize virus genome sequences and alter their growth kinetics. In some embodiments, the method can be used to optimize the growth of viral strains used for vaccine production. A number of embodiments of the disclosure have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. By way of non-limiting illustration, examples of certain embodiments of the present disclosure are given below. EXAMPLES The following examples are set forth below to illustrate the compositions, devices, methods, and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art. Example 1: Transient RNA structures cause aberrant influenza virus replication and innate immune activation. The influenza A virus (IAV) RNA polymerase produces both full-length and aberrant RNA molecules, such as defective viral genomes (DVG) and mini viral RNAs (mvRNA), during infection. Subsequent innate immune activation involves the binding of host pathogen receptor retinoic acid-inducible gene I (RIG-I) to viral RNAs. However, it is not clear what factors determine which influenza A virus RNAs are RIG-I agonists. Herein, evidence is provided that RNA structures, called template loops (t-loop), stall the viral RNA polymerase and contribute to innate immune activation by mvRNAs during influenza A virus infection. Impairment of replication by t-loops depends on the formation of an RNA duplex near the template entry and exit channels of the RNA polymerase, and this effect is enhanced by mutation of the template exit path from the RNA polymerase active site. Overall, these findings are supportive of a mechanism involving polymerase stalling that links aberrant viral replication to the activation of the innate immune response. During an IAV infection, the virus introduces eight ribonucleoproteins (RNP) into the host cell nucleus. These RNPs consist of oligomeric viral nucleoprotein (NP), a copy of the viral RNA Attorney Docket No.11676-003WO1 polymerase, and one of the eight segments of single stranded negative sense viral RNA (vRNA) that make up the viral genome. The vRNA segments range from 890 to 2341 nt in length, but all contain conserved 5ʹ triphosphorylated, partially complementary 5ʹ and 3ʹ termini. These termini serve as promoter for the RNA polymerase, but also as agonist of RIG-I. In the context of an RNP, the termini are bound by the RNA polymerase subunits PB1, PB2, and PA, and during viral replication, a second RNA polymerase is recruited to the RNP to encapsulate nascent RNA. It has been contemplated that binding of the viral RNA polymerase to the vRNA termini reduces RIG-I binding to the vRNA segments and it is not clear when or where RIG-I gains access to viral RNAs. In addition to full-length vRNA and cRNA molecules, the viral RNA polymerase can produce aberrant RNAs that are shorter than the vRNA or cRNA template from which they derive. Such aberrant RNAs include defective viral genomes (DVGs) and mini viral RNAs (mvRNA), which contain internal deletions between the conserved 5ʹ and 3ʹ termini. Both DVGs and mvRNAs can bind RIG-I and activate innate immune responses, but only DVGs require viral NP during viral replication while mvRNAs do not. It is presently not fully understood what determines the ability of DVGs and mvRNAs to activate RIG-I or how they are made. Interestingly, the RNA polymerases of highly pathogenic avian H5N1 and pandemic 1918 H1N1 IAV produce higher mvRNA levels than the RNA polymerase of lab adapted H1N1 IAV, showing that there is a correlation between adaptive mutations in the RNA polymerase, mvRNA production, and innate immune activation in infections with highly pathogenic IAV. Herein, this example examines the role of mvRNAs in innate immune activation in more detail. mvRNAs are generated, in part, via a copy-choice mechanism that results in the loss of an internal genome segment sequence, similar to what has been observed for DVGs (Figure 1B). As a result, RNA sequences or structures that do not normally reside side-by-side in the full-length genome segments are brought closer to each other in the nascent RNA, resulting in the formation of novel RNA structures (Figure 1B). Once generated, mvRNAs can be replicated by the viral RNA polymerase in the absence of NP. Inherently, the RNA polymerase is not impaired by RNA structures in an mvRNA template and it can replicate and transcribe an mvRNA containing a copy of the aptamer Spinach, a highly-structured RNA capable of stabilizing the fluorophore DFHBI (Figure 6). However, it is not known if other RNA secondary structures or certain sequence combinations could impair mvRNA replication or play a role in the activation of the innate immune response during IAV infection, as for instance has been observed for paramyxovirus infections. Herein, a previous model is advanced on the effect of mvRNAs on the innate immune response and provide evidence that mvRNAs capable of inducing innate immune responses contain RNA structures that can reduce the activity of the IAV RNA polymerase. Attorney Docket No.11676-003WO1 Results Induction of IFN- ^ promoter activation by mvRNAs is sequence dependent mvRNAs bind RIG-I and activate the MAVS signaling cascade, but it is unclear what determines whether an IAV mvRNA is an inducer of the innate immune response. To systematically investigate if the sequence or secondary structure of an mvRNA can affect IAV RNA polymerase activity and innate immune activation, five segment 5-derived mvRNA templates were engineered. Each engineered mvRNA had a length of 71 nt (NP71.1-NP71.5), but a different internal sequence (Table 1). The positive control mvRNAs were 56- and 76-nt long mvRNAs, which were previously constructed from segment 5 (NP56 and NP76, respectively), while the negative control mvRNA was a 47-nt long mvRNA derived from segment 5 (NP47) that is unable to bind RIG-I and induce a strong IFN signal. To validate the test setup, increasing amounts of in vitro transcribed NP76 was transfected into HEK 293T cells and a strong increase in IFN- ^ promoter activity was found that saturated at a ~50-fold induction, while the NP47 induced a lower activity (Figure 1B). These observations show how these RNAs differentially induce IFN- ^ promoter activity when they are transfected into the cytoplasm. Subsequently the IFN- ^ promoter activation was validated by the NP47, NP56 and NP76 mvRNA templates during replication by the IAV RNA polymerase. To this end, plasmids expressing the viral RNA polymerase subunits PB1, PB2 and PA, a plasmid expressing NP, and a plasmid expressing the NP76 template mvRNA were transfected into HEK 293T cells. Primer extension analysis showed efficient amplification of NP47, NP56 and NP76, as well as the production of several smaller aberrant RNA products that were shorter than template the mvRNA in the case of NP56 and NP76 (Figures 1C and 7). IFN- ^ promoter activation by NP56 and NP76, but not NP47 was observed. These results thus indicate that like the full-length vRNA segments, mvRNAs themselves can also serve as template for aberrant RNA synthesis. Fractionation of cells in which NP76 was replicated showed that the NP76 mvRNA template was present in the nuclear, cytoplasmic, and mitochondrial fractions, whereas the aberrant RNAs produced from the NP76 template were present in the nucleus only (Figure 7). Since IAV RNA is predominantly detected in the cytoplasm of the host cell, these results show that the mvRNA template, and not aberrant products shorter than the template mvRNA, play a role in innate immune activation. Following the characterization of these assays, the replication and IFN- ^ promoter activation was analyzed by the engineered mvRNA templates and found that three of these templates were efficiently replicated (NP71.1, NP71.4 and NP71.5), while the other two (NP71.2 and NP71.3) were not (Figure 1C). Interestingly, among the engineered mvRNAs, templates that Attorney Docket No.11676-003WO1 were poorly replicated showed higher IFN- ^ promoter activity and aberrant RNA synthesis (i.e., the production of RNA products containing deletions relative to the template; Figure 8A) than the three mvRNA templates that were efficiently replicated (Figure 1C). RT-qPCR analysis of cells replicating NP71.1 and NP71.2 confirmed that endogenous IFN- ^ mRNA levels were increased when NP71.2 was replicated (Figure 1D). To confirm that the NP71.2 had the ability to induce innate immune activation during viral infection, NP71.1 and NP71.2 was pre-expressed in absence of viral RNA polymerase and NP in HEK 293T cells. After 24 hours, the cells were infected with 3 MOI influenza virus A/WSN/1933 (H1N1) for 8 hours. As shown in Figure 8B, pre-expression of NP71.1 and NP71.2 had no effect on segment 6 replication or PB1 protein expression. In addition, phosphorylation of IRF3 after pre-expression of NP71.1 but not NP71.2 was observed. While this is shows MAVS signaling pathway activation through replication of mvRNA by the viral RNA polymerase, amplification of the exogenous mvRNAs could not be detected because they need to compete with the eight endogenous vRNA templates for binding to the viral RNA polymerase expressed by the virus. Thus, it was not determined whether the engineered mvRNAs affect the MAVS signaling pathway in the same way during viral infection as in the RNP reconstitution experiments. To exclude that a differential recognition of the engineered mvRNAs by host pathogen receptors of the host cell was responsible for the observed increased IFN- ^ promoter activity on the NP71.2 and NP71.3 mvRNAs, total RNA was isolated from HEK 293T transfections and re- transfected equal amounts of these RNA extracts together with IFN- ^ and Renilla reporter plasmids into HEK 293T cells. Re-transfection of NP71.1-NP71.5 showed an inverse pattern of IFN- ^ promoter activation in comparison to Fig. 1C, whereby abundant mvRNAs induced more IFN- ^ promoter activity than the least abundant mvRNAs (Figure 8C), showing that there is no inherent difference between the mvRNA in their ability to activate IFN- ^ promoter activity. Instead, these results indicated that impaired active viral replication determines whether an mvRNA will activate innate immune signaling in the context of an RNP. To verify that the different replication efficiencies had not been the result of the effect of NP71.2 and NP71.3 on the innate immune response, these mvRNAs and the WSN RNA polymerase were also expressed in MAVS ^-/- IFN::luc HEK 293 cells. These MAVS ^-/- cells do not express endogenous MAVS (Figure 9A), blocking any RIG-I mediated innate immune signaling, but overexpression of a MAVS-FLAG plasmid still triggers IFN- ^ promoter activity, indicating that the IFN- ^ reporter is still functional (Figure 9B). Expression of NP71.1-NP71.5 in the MAVS- ^/- cells did not induce IFN- ^ promoter activity (Figure 9C). Subsequent primer extension analysis Attorney Docket No.11676-003WO1 showed that the differences in replication between NP71.1-NP71.5 had been maintained in the MAVS ^-/- cells (Figure 9C), demonstrating that the differential replication efficiency is not dependent on the innate immune response. To investigate whether the effect of the NP71.3 and NP71.4 mvRNAs was specific to the WSN polymerase, these mvRNAs were expressed alongside the pandemic H1N1 A/Brevig Mission/1/18 (abbreviated as BM18) or the highly pathogenic avian H5N1 A/duck/Fujian/01/02 (abbreviated as FJ02) RNA polymerases. The BM18 and FJ02 RNA polymerases were impaired on the NP71.2 and NP71.3 mvRNA templates and triggered a stronger IFN- ^ promoter activity on the NP71.3 template relative to the NP71.1 template (Figure 10). The BM18 RNA polymerase also produced short aberrant RNA products, while the FJ02 RNA polymerase did not, despite inducing IFN- ^ promoter activity (Figure 10). Together, these results show that the mvRNA template is the innate immune agonist, rather than the aberrant RNA products derived from the mvRNA template, and that innate immune activation is dependent on a sequence-specific interaction between the active IAV RNA polymerase and the mvRNA template. T-loops affect viral polymerase activity and IFN- ^ promoter activation The viral RNA template enters and leaves the active site of the IAV RNA polymerase as a single strand through the entry and exit channels, respectively (Figure 2A). However, the IAV genome contains various RNA structures that need to be unwound. Moreover, unwinding of these structures may lead to the formation of transient RNA structures upstream or downstream of the RNA polymerase that may modulate RNA polymerase activity (Figure 2A), while base pairing between a part of the template that is entering the RNA polymerase and a part of the template that has just been duplicated may trap the RNA polymerase in a template loop (t-loop) (Figure 2A). To systematically analyze what (transient) RNA structures are present during replication, a sliding- window algorithm was used to calculate the minimum free energy (ΔG) for every putative t-loop as well as every putative secondary RNA structure upstream and downstream of the RNA polymerase (Figures 11A and 11B). For each position analyzed, 20 nt were excluded from the folding analysis for the footprint of the IAV RNA polymerase and 12 nt from the 5′ terminus, which is stably bound by the RNA polymerase prior to replication termination. As shown in Figure 2B and Figure 11C, the analysis revealed that NP71.2 and NP71.3 are unique among the engineered mvRNA templates in forming t-loop structures around nucleotide 29 of the positive sense replicative intermediate (cRNA), but not the negative sense (Figure 11D), showing that t-loops in the positive sense mvRNA template modulate RNA polymerase activity. The likelihood that the t- Attorney Docket No.11676-003WO1 loops form in the context of other secondary structures was calculated as the difference (ΔΔG) between the computed ΔG values for the individual structures (Figure 2B). To confirm that t-loops affect RNA polymerase processivity and IFN- ^ promoter activity, two A-U base pairs of the NP71.2 t-loop duplex were replaced with two G-U base pairs, creating NP71.6 (Figure 2B and 12A). Using the sliding window analysis, this mutation was confirmed to make t-loop formation near nucleotide 29 less favorable (Figure 2B). Following expression of NP71.1, NP71.2 and NP71.6, replication of the NP71.6 mvRNA was increased relative to the NP71.2 mvRNA, our control mvRNAs, and the NP71.1 mvRNA (Figure 2C and 12B). In addition, destabilization of the t-loop reduced the induction of the IFN- ^ promoter activity (Figure 2C). By contrast, mutating the stem of the t-loop of the NP71.2 mvRNA template such that the t-loop around nucleotide 29 was maintained (Figure 12C; NP71.7-8), replication remained reduced and IFN- ^ reporter activity increased relative to the NP71.1 mvRNA (Figure 12C and 12D). Replication of mvRNAs with a t-loop led to the production of short aberrant RNA products that likely contained internal deletions. However, increases in aberrant RNA levels were not correlated with increases in IFN- ^ reporter activity, in line with the results in Figure 1C and Figure 6, and indicated that the mvRNA template is the agonist of IFN- ^ reporter activity. Analysis of control mvRNA templates showed that NP56 and NP76 contain weak t-loops in the first half of both the positive and negative sense template, while stronger t-loops exist in the second half for the NP56 template (Figure 11E). Together these results indicate that t-loops can negatively affect IAV RNA synthesis and stimulate innate immune signaling during IAV replication. T-loops reduce RNA polymerase processivity in vitro The mvRNAs NP71.2 and NP71.3 contain a t-loop in the first half of the positive sense mvRNA template. To confirm that t-loops also affect RNA polymerase activity in the negative sense, three additional 71-nt long mvRNA templates were engineered with t-loops in different locations of the template (NP71.10-12) (Table 1; Figure 3A). Expression of these mvRNA templates together with the subunits of the viral RNA polymerase in HEK 293T cells led to strongly reduced NP71.10 and NP71.11 mvRNA levels and slightly reduced NP71.12 mvRNA levels (Figure 3B). In line with other results (Figure 1C and 2C), IFN- ^ promoter activity was increased for the NP71.11 and NP71.12 templates relative to the NP71.1 mvRNA, while the NP71.10 mvRNA did not induce IFN- ^ promoter activity because it was too poorly or not fully replicated (Figure 3B). To investigate if t-loops affect RNA polymerase processivity in vitro, the WSN RNA polymerase was purified from HEK 293T cells using tandem-affinity purification (TAP) and Attorney Docket No.11676-003WO1 incubated the enzyme with the NP71.1 and NP71.10 mvRNA templates in the presence of NTPs. Following denaturing PAGE and autoradiography, a main product of approximately 71 nt in reactions was observed containing the NP71.1 control mvRNA (Figure 3C). By contrast, incubations with the NP71.10 mvRNA template resulted in products up to approximately 27 nt in length, in agreement with the location of the t-loop in the first half of the mvRNA template (Figure 3A). Moreover, the observed partial extension of the product offered a possible explanation for the reduced RNA levels in cell culture and the lack of IFN- ^ promoter activity induction by the NP71.10 template (Figure 3B). T-loops do not induce template release in vitro To investigate if t-loop containing templates remained stably bound to the RNA polymerase or triggered template dissociation, mOrange-tagged RNA polymerase was immobilized on magnetic RFP-trap beads, and incubated these immobilized complexes with radiolabeled template. After removal of unbound template by three washes with binding buffer, ApG and nucleotides were added to initiate RNA synthesis and complexes incubated at 30 ^o C for 15 min. Next, the immobilized complexes were washed three times to remove dissociated RNA, and the reactions stopped with formaldehyde/EDTA loading dye. Analysis of the bound and unbound radiolabeled RNA levels by dot blot and autoradiography showed no difference between the NP71.1, NP71.10 and NP71.11 templates (Figure 13A). To rule out that released template were rebound upon dissociation from the RNA polymerase, excess unlabeled NP71.1 template was added as RNA polymerase trap at the start of the reaction. Again, no difference between the templates was observed (Figure 13A). To confirm that the immobilized RNA polymerases were active, RNA polymerase bound to unlabeled template mvRNA was immobilized on magnetic beads as described above. Next, ApG, NTPs, and radiolabeled GTP was added and incubated the immobilized complexes at 30 ^o C for 15 min. Following removal of unincorporated NTPs by three washes with binding buffer, the nascent RNA in solution as well as associated with the immobilized complexes was analyzed by denaturing PAGE and autoradiography. As shown in Figure 13B, partially extended and full-length nascent RNAs remained associated with the immobilized RNA polymerases. Partially extended nascent RNAs were also found in the unbound fraction. Addition of inactive RNA polymerase (PB1a) to serve as encapsulating polymerase in RNA polymerase dimers increased the release of partially extended nascent RNAs, but not the release of full-length RNAs. Together, these results show that t-loops do not induce template release upon RNA polymerase stalling and that partially Attorney Docket No.11676-003WO1 extended nascent strands can be separated by RNA polymerase from the template strand and released. PB1 K669A increases t-loop sensitivity and IFN- ^ promoter activation In the IAV RNA polymerase elongation complex, the 3ʹ terminus of the template is guided out of the template exit channel via an exit groove on the outside of the thumb subdomain. This groove consists of PB1 and PB2 residues, and leads to promoter binding site B (Figure 2A and 4A). Since this exit groove and the template entry channel reside next to each other at the top of the RNA polymerase (Figure 2A and 4A), perturbation of the path of the 3ʹ terminus out of the exit channel may stabilize t-loop formation, reduce RNA polymerase activity, and increase IFN- ^ promoter activation (Figure 2A and 4A). It was observed that avian adaptive mutations of highly pathogenic IAV RNA polymerases that increase IFN promoter activation in vitro, such as PB2 M81T (Figure 4A), reside next to the template exit groove. It was therefore contemplated that other mutations near the template exit channel may make the IAV RNA polymerase more sensitive to t- loops. To test if dysregulation of the exit groove leads to more IFN- ^ promoter activation, PB1 lysine 669, which resides at the start of the exit groove (Figure 3B), were mutated to alanine (K669A). Mutation of this residue had no effect on RNA polymerase activity in the presence of a full-length segment 6 template (Figure 3C) or the NP71.1 and NP71.6 mvRNA templates that do not contain a stable t-loop (Figure 3D and 3E). However, when the K669A mutant was expressed together with the NP71.2, NP71.11 or NP71.12 mvRNAs, which do contain a t-loop in either the positive or negative sense, the K669A mutant displayed greatly reduced RNA polymerase activity (Figure 3D and 3E), showing that the K669A mutation increases the processivity defect induced by t-loops. In contrast, the effect of K669A on IFN- ^ promoter activity was more difficult to interpret, because while the IFN- ^ promoter activity was considerably increased on the t-loop containing templates (Figure 3B and 3E), the K669A mutant also induced significantly higher IFN- ^ promoter activity relative to the wild-type RNA polymerase on the control templates. These results show that the K669A mutation has two effects: increase the base-level of the RNA polymerase to trigger FN- ^ promoter activity on templates without a known or destabilized t-loop through an unknown mechanism, and make the RNA polymerase more sensitive to disruption by a t-loop and trigger additional IFN- ^ promoter activity through this mechanism. Attorney Docket No.11676-003WO1 Differential IFN- ^ promoter activation by natural mvRNAs mvRNAs are produced during IAV infection in vitro and in vivo. To study how their sequence and abundance varies, RNA extracted from ferret lungs was examined 1 day post infection with BM18 for 1 day and A549 cells infected with WSN for 8 hours (see Examples 2-5 for mvRNA sequences). Although no quantitative comparisons can be made due to the different infection conditions, a strikingly similar variation in mvRNA sequence and abundance was found (Figure 5A and 5B). To investigate the implications of these mvRNA differences on the activation of the IFN- ^ promoter, ten WSN segment 2 mvRNAs (randomly selected over a range of copy numbers and lengths; Figure 14A) were cloned into pPolI plasmids (mvRNAs A-J; Table 2). Analysis of the ΔΔG values for these mvRNAs revealed potential t-loops in the first half of the sequence for mvRNAs C, D, H and J, and t-loops in the second half of the sequence for mvRNAs E, F and G (Figure 5C). Subsequent expression of the authentic WSN mvRNAs alongside the WSN RNA polymerase in HEK 293T cells showed significant differences in mvRNA amplification (Figure 5D). These differences were correlated with the abundance detected by next generation sequencing (NGS) for seven of the cloned mvRNAs (Figure 14B). In addition, replication of mvRNAs C, D and J leads to the appearance of products shorter than the template mvRNA (Figure 5D), and the appearance of these products is correlated with a reduced replication of the template mvRNA, in line with the findings in Figure 1. To investigate if the different segment 2 mvRNA levels influenced the innate immune response, the IFN- ^ promoter activity was measured. IFN- ^ promoter activity varied greatly, with mvRNAs C, D and J inducing the strongest response (Figure 5D). Templates I and G, the two shortest mvRNAs at 52 and 40 nt long, induced the lowest IFN- ^ promoter activity, in line with previous observations that short mvRNAs <56 nt do not stimulate RIG-I and Figure 1C. With mvRNAs I and G excluded due to their short size, these observations indicate that the IFN- ^ promoter activity is negatively correlated with mvRNA template level for mvRNAs >56 nt (Figure 5E). Moreover in Figure 1, t-loops in the first half of the template affect RNA polymerase processivity, the IFN- ^ promoter activity was negatively correlated with the mean ΔΔG of the first half of the template (Figure 5F). Weaker correlations were observed between the mvRNA length and IFN- ^ induction, or the mvRNA length and mvRNA replication (Figures 15A and 15B). To exclude that a differential recognition of the mvRNAs was responsible for the observed anti-correlation, total RNA was isolated from HEK 293T transfections and re-transfected equal amounts of these RNA extracts into HEK 293T cells. As shown in Figure 16A, no significant difference among the segment 2 mvRNAs longer than 56 nt was observed. The mvRNAs G and I Attorney Docket No.11676-003WO1 failed to induce a strong response due to their short length. To exclude that the different mvRNA levels had been the result of their different effects on the innate immune response, the segment 2 mvRNAs were also expressed in MAVS ^-/- IFN::luc HEK 293 cells. Following expression of the segment 2 mvRNAs, no IFN- ^ promoter activity was observed (Figure 16B). Primer extension analysis showed no significant reduction in mvRNA steady-state levels compared to wildtype cells (Figure 16C), indicating that the replication of authentic mvRNAs is not impacted by innate immune activation. To confirm that mvRNAs from other viral segments have differential effects on the innate immune response, two segment 3 mvRNAs and four segment 4 mvRNAs (Table 3) were cloned from the mvRNA sequences identified during infection into pPol expression plasmids and transfected these plasmids into HEK 293T cells. As shown in Figure 17, PA and HA mvRNAs induced both high and low levels of IFN- ^ promoter activity compared our NP71.1 control. Together, these results indicate that viral infections produce mvRNAs with different mechanisms to induce IFN- ^ promoter activity, and that t-loops play a key role in the mvRNAs inducing IFN- ^ promoter activity by affecting the ability of the RNA polymerase to efficiently replicate them. Discussion Two factors important for inducing an innate immune response in IAV infections are active viral replication and the binding of viral RNA molecules to RIG-I. Herein, the effect of IAV mvRNAs, which do not need viral NP to be replicated by the viral RNA polymerase, was examined. Evidence is provided that impeded viral RNA polymerase processivity by t-loops is a mechanism that contributes to the activation of innate immune signaling by mvRNAs. While there is no direct assay to measure or visualize t-loop formation in mvRNAs yet and can thus not rule out other or additional mechanisms, it is postulated that t-loops form when the 3ʹ terminus or a sequence near the 3ʹ terminus of the template can hybridize with an upstream part of the template (Figure 2A). RNA polymerase is thought to unwind a single t-loop, but the formation of several successive t-loops in the first half of the mvRNA stalls the RNA polymerase (Figure 3C). It is presently still unclear why a strong correlation between reduced processivity and t-loops is observed with t-loops in the first half of the template and not with downstream t-loops. It is unclear how RIG-I gains access to the t-loop containing mvRNA once the polymerase has stalled (Figure 4G). RNA polymerase stalling does not result in release of the RNA template from the active site (Figure 3D) because the RNA polymerase remains associated with the 5ʹ terminus of the template prior to replication termination. This means that it is still unclear how mvRNA templates accumulate in the cytoplasm and mitochondria (Figure 7). Attorney Docket No.11676-003WO1 One mechanism is that t-loops affect influenza RNA polymerase activity on full-length viral RNAs or DVGs. However, it is more likely that t-loops form only on partially formed RNPs or NP-less templates, since NP may modulate the presence and location of secondary RNA structures. During viral RNA synthesis, NP dissociates and binds viral RNA in a manner that is coordinated by the viral RNA polymerase. When NP levels are reduced, aberrant RNPs or NP-less RNA products form in which secondary RNA structures that are absent in the presence of NP contribute to t-loop formation and RNA polymerase stalling. Indeed, this model explains how reduced viral NP levels stimulate aberrant RNA synthesis and innate immune activation. A mutation near the template exit channel increases the RNA polymerase sensitivity to t-loops (Figure 4). It was previously observed that avian adaptive mutations, such as PB2 N9D or M81T, reside near the template exit channel of highly pathogenic IAV RNA polymerases and that they stimulate IFN- ^ promoter activity. Thus, mutations make the RNA polymerase more sensitive to mvRNAs, which are produced at high levels by highly pathogenic IAV RNA polymerases, and this sensitivity leads to increased RNA polymerase stalling by t-loops and IFN- ^ promoter activation. During viral infection, mvRNA molecules of various lengths and abundances are produced. It was found that mvRNA abundance is not the best estimate for innate immune activation. An updated model in which mvRNAs that are poorly replicated contribute most to the activation of the innate immune system is contemplated, and thus that activation of the innate immune response is dependent on a template sequence context. Material and methods Viral protein and RNA expression plasmids pcDNA3-based plasmids expressing influenza A/WSN/33 (H1N1) proteins PB1, PB2 PA, NP, PB2-TAP and the active site mutant PB1a (D445/D446A). Mutation K669A was introduced into the pcDNA3-PB1 plasmid by site-directed mutagenesis. mvRNA templates were expressed under the control of the cellular RNA polymerase I promoter from pPolI plasmids. PB1 mvRNA templates were generated by site-directed mutagenesis PCR deletion of pPolI-PB1. Short vRNA templates were created based on the pPolI-NP47 plasmid using the SpeI restriction site. Luciferase assay Firefly luciferase reporter plasmid under the control of the IFNB promoter (pIFΔ(-116)lucter) and constitutively expressing Renilla luciferase plasmid (pcDNA3-Renilla). The MAVS-FLAG Attorney Docket No.11676-003WO1 expression vector and corresponding empty vector were cloned based on the pFS420, using the MAVS WT plasmid (pEF-HA-MAVS). Cells, transfections and infections Human embryonic kidney (HEK) 293T, Madin-Darby Canine Kidney (MDCK), and A549 cells were originally sourced from the American Type Culture Collection. All cells were routinely screened for mycoplasma. HEK293 wild-type and MAVS ^-/- cells expressing luciferase under the control of the IFNB promoter were a kind gift from Dr J. Rehwinkel. All cell cultures were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma) with 10% fetal bovine serum (FBS) (Sigma) and 1% L-Glutamine (Sigma). Transfections of HEK293T or HEK293 cell suspensions were performed using Lipofectamine 2000 (Invitrogen) and Opti-Mem (Invitrogen) following the manufacturer’s instructions, and transfection of confluent, adherent HEK 293T cells were performed using PEI (Sigma) and Opti-Mem. Infections were performed at MOI 3. Antibodies and western blotting IAV proteins were detected using rabbit polyclonal antibodies anti-PB1 (GTX125923; GeneTex), anti-PB2 (GTX125926; GeneTex), and anti-NP (GTX125989; GeneTex) diluted 1:1000 in TBSTM (TBS/0.1% Tween-20 (Sigma)/5% milk). Cellular proteins were detected using the rabbit polyclonal antibodies anti-GAPDH (GTX100118; GeneTex) diluted 1:4000 in TBSTM, and anti- RNA Pol II (ab5131; Abcam) diluted 1:100 in TBSTM; the mouse monoclonal antibodies anti-MAVS E-3 (sc-166583; Santa Cruz) diluted 1:200 in TMSTM, and Mito tracker [113-1] (ab92824; Abcam) diluted 1:1000 TBSTM; and the rat monoclonal antibody anti-tubulin (MCA77G; Bio-Rad) diluted 1:1000 in TBSTM. Mouse monoclonal antibody anti-FLAG M2 (F3165; Sigma) diluted at 1:2000 was used to detect MAVS-FLAG. Secondary antibodies IRDye 800 Donkey anti-rabbit (926-32213; Li-cor), IRDye 800 Goat anti-mouse (926-32210; Li-cor), IRDye 680 Goat anti-mouse (926-68020; Li-cor), and IRDye 680 Goat anti-rat (926-68076; Li-cor), were used to detect western signals with a Li-cor Odyssey scanner. RNP reconstitution assays and RNA sequence analysis Infections and RNA analyses using primer extensions were performed as described previously. mvRNA identification from next generation sequencing data was essentially performed, using data deposited in the Sequence Read Archive under accession number SUB3758924. Aberrant RNA products observed in various experiments were gel extracted, Topo cloned and sequenced using Sanger sequencing. Alignments were analyzed using Clustal Omega and visualized using Espript 3. Attorney Docket No.11676-003WO1 T-loop analysis was performed using a custom Python script. Briefly, 20 nt of the template sequence were blocked off to represent the footprint of the viral RNA polymerase. This footprint was then moved in 1 nt increments along the template (Figure 11A and 11B). T-loop formation was assessed by computing the ΔG of duplex formation between a stretch of 10 nt upstream of the footprint and 10 nt downstream of the footprint. The formation of upstream and downstream structures was computed for 24 nt windows (the footprint of NP) upstream and downstream of the moving footprint. The ΔΔG was computed by subtracting The ViennaRNA package commands duplex-fold and cofold were used to compute the ΔG values. Luciferase-based IFN expression assays To measure IFN expression in RNP reconstituted HEK293T or HEK293 cells, luciferase assays were carried out 24 h post-transfection. RNP reconstitutions were carried out in a 24-well format by transfecting 0.25 µg of the plasmids pcDNA3-PB1, pcDNA3-PB2, pcDNA3-PA, pcDNA3- NP and a pPolI plasmid expressing a mvRNA template. HEK293T and HEK293 cells were additionally co-transfected with 100ng of the plasmids pIFΔ(-116)lucter and pcDNA3-Renilla. Cells were harvested in PBS and resuspended in an equal volume of Dual-Glo Reagent (Promega) followed by Dual-Glo Stop & Glo reagent (Promega). Firefly and Renilla luminescence were measured after 10 minutes incubation with each reagent respectively as per manufacturer’s instructions for the Dual- Glo Luciferase Assay System (E2920, Promega) using the Glomax luminometer (Promega). IAV polymerase purification and in vitro activity assay Influenza virus A/WSN/33 (H1N1) recombinant polymerases were purified from HEK293T cells. Ten cm plates of adherent cells were transfected with 3 µg of pcDNA3-PB1, pcDNA3-PB2- TAP and pcDNA3-PA with PEI (Sigma). Forty-eight hours post-transfection, cells were harvested in PBS and lysed on ice for 10 min in 500 µl lysis buffer (50 mM hepes pH 8.0, 200 mM NaCl, 25% glycerol (Sigma), 0.5% Igepal CA-630 (Sigma), 1mM β-mercaptoethanol (Bio-Rad), 1x PMSF (Sigma), 1x Protease Inhibitor cocktail tablet (Roche). Lysates were cleared by centrifugation at 17000 g for 5 min at 4°C, diluted in 2ml NaCl (Sigma), and bound to pre-washed IgG Sepharose beads (Cytiva) for 2 h at 4°C. Beads were pre-washed 3x in binding buffer (10mM Hepes pH 8.0, 0.15 M NaCl, 0.1% Igepal CA-630, 10% glycerol, 1x PMSF). After binding, beads were washed 3x in binding buffer and 1x in cleavage buffer (10mM Hepes pH 8.0 (Sigma), 0.15M NaCl, 0.1% Igepal CA-630, 10% glycerol, 1x PMSF, 1mM DTT). Beads were cleaved with AcTEV protease (Invitrogen) overnight at 4°C, and cleared by centrifugation at 1000 g for 1 min. Activity assays using immobilized RNA polymerase were performed using an RNA polymerase with an mOrange-tag on Attorney Docket No.11676-003WO1 the PB2 subunit. The purified polymerase was immobilized using magnetic RFP-trap beads (Chromotek). Cell fractionation Fractionation of transfected cells into cytoplasmic, mitochondrial, and nuclear components was carried out using the Abcam Cell Fractionation Kit (Abcam) following the manufacturer’s instructions, with volumes adjusted based on the number of cells. Samples of unfractionated whole cells in Buffer A were retained as input controls. Whole cells and sub-cellular fractions were dissolved in Trizol, for RNA extraction and analyzed as described above, or in 10%-SDS protein-loading buffer, for protein expression analysis by SDS-PAGE and western blot. Statistical testing Statistical testing was carried out using GraphPad Prism 9 software. Error bars represent standard deviations, and either individual data or group mean values are plotted. One-way analysis of variance (ANOVA) with Dunnett’s test for multiple comparisons was used to compare multiple-group means to a normalized mean (e.g., IFN induction or RNA template replication). Two-way ANOVA with Sidak’s test for multiple comparisons was used to compare multiple pairs of group means (e.g., between two cell types, HEK293 WT to HEK293 MAVS ^-/- ). Example 2: Fasta file 1. WSN mvRNA sequences. 1) SEQ ID NO: 31 - WSN_NP_61 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATAGAAAAATACCCTTG TTTCTACT 2) SEQ ID NO: 32 - WSN_PB1_57 AGCGAAAGCAGGCAAACCATTTGAATGGATTTCATGAAAAAATGCCTTGTTTCT ACT 3) SEQ ID NO: 33 - WSN_PB1_57 AGCGAAAGCAGGCAAACCATTTGAATGTCCTTCATGAAAAAATGCCTTGTTTCT ACT 4) SEQ ID NO: 34 - WSN_PB1_66 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGCAAACCATTTGAATGTTTAGCTTGTCCTTCATGAAAAAATGC CTTGTTTCTACT SEQ ID NO: 35 - WSN_NP_65 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTAAAGAAAAATACC CTTGTTTCTACT SEQ ID NO: 36 - WSN_HA_44 AGCAAAAGCAGGGGAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 37 - WSN_NA_70 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCTGACAAGTAGTTTGTTCAAAA AACTCCTTGTTTCTACT ) SEQ ID NO: 38 - WSN_PB1_62 AGCGAAAGCAGGCAAACCATTTGAATAGCTTGTCCTTCATGAAAAAATGCCTTG TTTCTACT ) SEQ ID NO: 39 - WSN_NP_70 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATTAAAGAAAA ATACCCTTGTTTCTACT 0) SEQ ID NO: 40 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAAAAATGCCT TGTTTCTACT 1) SEQ ID NO: 41 - WSN_PB1_69 AGCGAAAGCAGGCAAACCATTTGAATGGATGTTAGCTTGTCCTTCATGAAAAAA TGCCTTGTTTCTACT 2) SEQ ID NO: 42 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 43 - WSN_PB1_62 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAAATGCCTTG TTTCTACT ) SEQ ID NO: 44 - WSN_PB1_68 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTCATGAAAAAA TGCCTTGTTTCTACT ) SEQ ID NO: 45 - WSN_HA_60 AGCAAAAGCAGGGGAAATTAGGATTTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 46 - WSN_PB1_68 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCTCCTTCATGAAAAAAT GCCTTGTTTCTACT ) SEQ ID NO: 47 - WSN_PB1_49 AGCGAAAGCAGGCAAACCATTTGAATTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 48 - WSN_PB1_56 AGCGAAAGCAGGCAAACTTTAGCTTGTCCTTCATGAAAAAATGCCTTGTTTCTA CT ) SEQ ID NO: 49 - WSN_PB2_60 AGCGAAAGCAGGTCAATTATATTCAATATCGAATAGTTTAAAAACGACCTTGTT TCTACT ) SEQ ID NO: 50 - WSN_PB1_60 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATATGAAAAAATGCCTTGTT TCTACT ) SEQ ID NO: 51 - WSN_NP_74 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTACGACAATTAAAG AAAAATACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 52 - WSN_NA_73 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAACAAGTAGTTTGTTCA AAAAACTCCTTGTTTCTACT ) SEQ ID NO: 53 - WSN_NA_62 AGCAAAAGCAGGAGTTTAAATGAATCCAAACTAGTTTGTTCAAAAAACTCCTTG TTTCTACT ) SEQ ID NO: 54 - WSN_NA_63 AGCAAAAGCAGGAGTTTAACACCATTGACAAGTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 55 - WSN_PB2_55 AGCGAAAGCAGGTCAATTATATTCCGAATAGTTTAAAAACGACCTTGTTTCTAC T ) SEQ ID NO: 56 - WSN_PB1_44 AGCGAAAGCAGGCAAACCATATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 57 - WSN_PA_64 AGCGAAAGCAGGTACTGATTCAAATTGCTATCCATACTGTCCAAAAAAGTACCT TGTTTCTACT ) SEQ ID NO: 58 - WSN_NP_70 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATAGAAAA ATACCCTTGTTTCTACT ) SEQ ID NO: 59 - WSN_HA_46 AGCAAAAGCAGGGGAAAATAAAAAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 60 - WSN_HA_61 AGCAAAAGCAGGGGAAAATAAAGATTTCAGAAATATAAGGAAAAACACCCTTG TTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 61 - WSN_PB1_65 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTGAAAAAATGC CTTGTTTCTACT ) SEQ ID NO: 62 - WSN_PB1_61 AGCGAAAGCAGGCAAACCATTTGAATGGTTGTCCTTCATGAAAAAATGCCTTGT TTCTACT ) SEQ ID NO: 63 - WSN_PB1_67 AGCGAAAGCAGGCAAACCATTTGAATGATTTAGCTTGTCCTTCATGAAAAAATG CCTTGTTTCTACT ) SEQ ID NO: 64 - WSN_PB1_60 AGCGAAAGCAGGCAAACCATTTGTAGCTTGTCCTTCATGAAAAAATGCCTTGTT TCTACT ) SEQ ID NO: 65 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATGTGAATTTAGCTTGTCCTTCATGAAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 66 - WSN_PA_66 AGCGAAAGCAGGTACTGATTTACTATTTGCTATCCATACTGTCCAAAAAAGTAC CTTGTTTCTACT ) SEQ ID NO: 67 - WSN_NP_69 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCAAA TACCCTTGTTTCTACT ) SEQ ID NO: 68 - WSN_NP_70 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCAAA ATACCCTTGTTTCTACT ) SEQ ID NO: 69 - WSN_NP_66 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTTAAAGAAAAATAC CCTTGTTTCTACT ) SEQ ID NO: 70 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATTAAAGAAAAATACCC TTGTTTCTACT ) SEQ ID NO: 71 - WSN_NP_57 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACAAAAATACCCTTGTTTCT ACT ) SEQ ID NO: 72 - WSN_NP_59 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTTAAAGAAAAATACCCTTGTTT CTACT ) SEQ ID NO: 73 - WSN_NP_55 AGCAAAAGCAGGGTAGATAATCACTCACAGAGAGAAAAATACCCTTGTTTCTAC T ) SEQ ID NO: 74 - WSN_NA_64 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCATAGTTTGTTCAAAAAACTCCT TGTTTCTACT ) SEQ ID NO: 75 - WSN_NA_71 AGCAAAAGCAGGAGTTTAAATGAATCCAACCATTGACAAGTAGTTTGTTCAAAA AACTCCTTGTTTCTACT ) SEQ ID NO: 76 - WSN_HA_64 AGCAAAAGCAGGGGAATGAGATTAGGATTTCAGAAATATAAGGAAAAACACCC TTGTTTCTACT ) SEQ ID NO: 77 - WSN_PB2_62 AGCGAAAGCAGGTCAATTATATTCAATATGGAGAATAGTTTAAAAACGACCTTG TTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 78 - WSN_PB2_57 AGCGAAAGCAGGTCAATTATATTCAATATGTAGTTTAAAAACGACCTTGTTTCT ACT ) SEQ ID NO: 79 - WSN_PB2_48 AGCGAAAGCAGGTCAATTATATTCATTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 80 - WSN_PB2_54 AGCGAAAGCAGGTCAATTATAGTCGAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 81 - WSN_PB2_49 AGCGAAAGCAGGTCAATTAGAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 82 - WSN_PB2_58 AGCGAAAGCAGGTCAATCAATTAGTGTCGAATAGTTTAAAAACGACCTTGTTTC TACT ) SEQ ID NO: 83 - WSN_PB1_68 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACGAAAAAA TGCCTTGTTTCTACT ) SEQ ID NO: 84 - WSN_PB1_73 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTCCTTCATGAA AAAATGCCTTGTTTCTACT ) SEQ ID NO: 85 - WSN_PB1_61 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAATGCCTTGT TTCTACT ) SEQ ID NO: 86 - WSN_PB1_63 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAAAATGCCTT GTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 87 - WSN_PB1_80 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGAATTTAGCTTGTCCT TCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 88 - WSN_PB1_47 AGCGAAAGCAGGCAAACCATTTGAATGAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 89 - WSN_PB1_48 AGCGAAAGCAGGCAAACCATTTGAATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 90 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATTTGAATGTAGCTTGTCCTTCATGAAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 91 - WSN_PB1_62 AGCGAAAGCAGGCAAACCATTTGATTAGCTTGTCCTTCATGAAAAAATGCCTTG TTTCTACT ) SEQ ID NO: 92 - WSN_PB1_43 AGCGAAAGCAGGCAAACCATTTAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 93 - WSN_PB1_40 AGCGAAAGCAGGCAAACTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 94 - WSN_PB1_50 AGCGAAAGCAGGCAAACTTGTCCTTCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 95 - WSN_NS_47 AGCAAAAGCAGGGTGACAAAGAAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 96 - WSN_NP_72 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGAGAA AAATACCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 97 - WSN_NP_88 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGGGAG TACGACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 98 - WSN_NP_91 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATAATGCAGAG GAGTACGACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 99 - WSN_NP_81 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAAGAGTACGACA ATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 100 - WSN_NP_62 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGGAAAAATACCCTT GTTTCTACT ) SEQ ID NO: 101 - WSN_NP_57 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAATACCCTTGTTTCT ACT ) SEQ ID NO: 102 - WSN_NP_58 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAAATACCCTTGTTTC TACT ) SEQ ID NO: 103 - WSN_NP_81 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGAATGCAGAGGAGTACGACA ATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 104 - WSN_NP_62 AGCAAAAGCAGGGTAGATAATCACTCATACGACAATTAAAGAAAAATACCCTT GTTTCTACT ) SEQ ID NO: 105 - WSN_NP_49 AGCAAAAGCAGGGTAGAGACAATTAAAGAAAAATACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 106 - WSN_NA_72 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAAAAGTAGTTTGTTCAA AAAACTCCTTGTTTCTACT ) SEQ ID NO: 107 - WSN_NA_70 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGACAAGTAGTTTGTTCAAAA AACTCCTTGTTTCTACT ) SEQ ID NO” 108 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAATTGACAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT ) SEQ ID NO: 109 - WSN_NA_45 AGCAAAAGCAGGAGTTTAAATTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 110 - WSN_NA_52 AGCAAAAGCAGGAGTTTAAATTAGTTTGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 111 - WSN_NA_62 AGCAAAAGCAGGAGTTTAAACCATTGACAAGTAGTTTGTTCAAAAAACTCCTTG TTTCTACT ) SEQ ID NO: 112 - WSN_M_70 AGCGAAAGCAGGTAGATATTGAAAGATGAGTCTTCTAACCGAGGTCGTAAAAA ACTACCTTGTTTCTACT ) SEQ ID NO: 113 - WSN_M_47 AGCGAAAGCAGGTAGATATTGAAAGATAAAACTACCTTGTTTCTACT ) SEQ ID NO: 114 - WSN_HA_52 AGCAAAAGCAGGGGAAAATAAAAACAACCAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 115 - WSN_HA_49 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGGAAAATAAAAACAAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 116 - WSN_HA_48 AGCAAAAGCAGGGGAAAATAAAAACAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 117 - WSN_HA_63 AGCAAAAGCAGGGGAAAATAAAAACATTTCAGAAATATAAGGAAAAACACCCT TGTTTCTACT ) SEQ ID NO: 118 - WSN_HA_67 AGCAAAAGCAGGGGAAAATAAAGATTAGGATTTCAGAAATATAAGGAAAAACA CCCTTGTTTCTACT ) SEQ ID NO: 119 - WSN_HA_61 AGCAAAAGCAGGGGAAAATTAGGATTTCAGAAATATAAGGAAAAACACCCTTG TTTCTACT ) SEQ ID NO: 120 - WSN_HA_58 AGCAAAAGCAGGGGAATAGGATTTCAGAAATATAAGGAAAAACACCCTTGTTT CTACT ) SEQ ID NO: 121 - WSN_PB2_57 AGCGAAAGCAGGTCAATTATATTCAATATGGAAAGAAAAAACGACCTTGTTTCT ACT ) SEQ ID NO: 122 - WSN_PB2_69 AGCGAAAGCAGGTCAATTATATTCAATATGGAAAGAGTCGAATAGTTTAAAAA CGACCTTGTTTCTACT ) SEQ ID NO: 123 - WSN_PB2_67 AGCGAAAGCAGGTCAATTATATTCAATATGTAGTGTCGAATAGTTTAAAAACGA CCTTGTTTCTACT ) SEQ ID NO: 124 - WSN_PB2_51 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGTCAATTATATTCAATATTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 125 - WSN_PB2_65 AGCGAAAGCAGGTCAATTATATTCAATATAGTGTCGAATAGTTTAAAAACGACC TTGTTTCTACT ) SEQ ID NO: 126 - WSN_PB2_59 AGCGAAAGCAGGTCAATTATATTCAATACGAATAGTTTAAAAACGACCTTGTTT CTACT ) SEQ ID NO: 127 - WSN_PB2_62 AGCGAAAGCAGGTCAATTATATTCAATGTGTCGAATAGTTTAAAAACGACCTTG TTTCTACT ) SEQ ID NO: 128 - WSN_PB2_52 AGCGAAAGCAGGTCAATTATATTCATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 129 - WSN_PB2_63 AGCGAAAGCAGGTCAATTATATTCATTAGTGTCGAATAGTTTAAAAACGACCTT GTTTCTACT 0) SEQ ID NO: 130 - WSN_PB2_44 AGCGAAAGCAGGTCAATTATATTAAAAACGACCTTGTTTCTACT 1) SEQ ID NO: 131 - WSN_PB2_60 AGCGAAAGCAGGTCAATTATATTTAGTGTCGAATAGTTTAAAAACGACCTTGTT TCTACT 2) SEQ ID NO: 132 - WSN_PB2_46 AGCGAAAGCAGGTCAATAATAGTTTAAAAACGACCTTGTTTCTACT 3) SEQ ID NO: 133 - WSN_PB2_51 AGCGAAAGCAGGTCAAGTGTCGAATAGTTTAAAAACGACCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 134 - WSN_PB1_73 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTTTTCTAA AAAATGCCTTGTTTCTACT ) SEQ ID NO: 135 - WSN_PB1_69 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTTTTAAAA TGCCTTGTTTCTACT ) SEQ ID NO: 136 - WSN_PB1_75 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTCTTCATG AAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 137 - WSN_PB1_65 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACAAAATGCC TTGTTTCTACT ) SEQ ID NO: 138 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 139 - WSN_PB1_61 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTAAAATGCCTTGT TTCTACT ) SEQ ID NO: 140 - WSN_PB1_73 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTGTCCTTCATGAA AAAATGCCTTGTTTCTACT ) SEQ ID NO: 141 - WSN_PB1_63 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCCATGAAAAAATGCCTT GTTTCTACT ) SEQ ID NO: 142 - WSN_PB1_60 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCTGAAAAAATGCCTTGTT TCTACT ) SEQ ID NO: 143 - WSN_PB1_80 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCTGAATTTAGCTTGTCCT TCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 144 - WSN_PB1_63 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCACCTTCATGAAAAAATGCCTT GTTTCTACT ) SEQ ID NO: 145 - WSN_PB1_65 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAGTCCTTCATGAAAAAATGCC TTGTTTCTACT ) SEQ ID NO: 146 - WSN_PB1_58 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCCATGAAAAAATGCCTTGTTTC TACT ) SEQ ID NO: 147 - WSN_PB1_52 AGCGAAAGCAGGCAAACCATTTGAATGGATGTAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 148 - WSN_PB1_63 AGCGAAAGCAGGCAAACCATTTGAATGGACTTGTCCTTCATGAAAAAATGCCTT GTTTCTACT ) SEQ ID NO: 149 - WSN_PB1_59 AGCGAAAGCAGGCAAACCATTTGAATGGGTCCTTCATGAAAAAATGCCTTGTTT CTACT ) SEQ ID NO: 150 - WSN_PB1_52 AGCGAAAGCAGGCAAACCATTTGAATGCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 151 - WSN_PB1_48 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGCAAACCATTTTCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 152 - WSN_PB1_61 AGCGAAAGCAGGCAAACCATTTTTTAGCTTGTCCTTCATGAAAAAATGCCTTGT TTCTACT ) SEQ ID NO: 153 - WSN_PB1_57 AGCGAAAGCAGGCAAACCATTAGCTTGTCCTTCATGAAAAAATGCCTTGTTTCT ACT ) SEQ ID NO: 154 - WSN_PB1_60 AGCGAAAGCAGGCAAACTGAATTTAGCTTGTCCTTCATGAAAAAATGCCTTGTT TCTACT ) SEQ ID NO: 155 - WSN_PB1_63 AGCGAAAGCAGGCAAACTAGTGAATTTAGCTTGTCCTTCATGAAAAAATGCCTT GTTTCTACT ) SEQ ID NO: 156 - WSN_PB1_56 AGCGAAAGCAGGCAAAATTTAGCTTGTCCTTCATGAAAAAATGCCTTGTTTCTA CT ) SEQ ID NO: 157 - WSN_PA_63 AGCGAAAGCAGGTACTGATTCAAAATGGAAGATTTTGTTCCAAAAAAGTACCTT GTTTCTACT ) SEQ ID NO: 158 - WSN_PA_58 AGCGAAAGCAGGTACTGATTCAAAATGGAAGATTTTAAAAAAGTACCTTGTTTC TACT ) SEQ ID NO: 159 - WSN_PA_53 AGCGAAAGCAGGTACTGATTCAAAATGGAAGATTAAAGTACCTTGTTTCTACT ) SEQ ID NO: 160 - WSN_PA_63 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGTACTGATTTATTTGCTATCCATACTGTCCAAAAAAGTACCTT GTTTCTACT ) SEQ ID NO: 161 - WSN_PA_44 AGCGAAAGCAGGTACTGAGTCCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 162 - WSN_NS_59 AGCAAAAGCAGGGTGACAAAGACATAATGGATCCAAACACTAACACCCTTGTT TCTACT ) SEQ ID NO: 163 - WSN_NS_60 AGCAAAAGCAGGGTGACAAAGACATAATGGATCCAAATAAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 164 - WSN_NS_52 AGCAAAAGCAGGGTGACAAAGACATAATGTAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 165 - WSN_NS_48 AGCAAAAGCAGGGTGACAAAGACATTAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 166 - WSN_NS_44 AGCAAAAGCAGGGTGACAAAGACAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 167 - WSN_NS_46 AGCAAAAGCAGGGTGACAAAGACAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 168 - WSN_NS_45 AGCAAAAGCAGGGTGACAAAGATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 169 - WSN_NS_67 AGCAAAAGCAGGGTGACAAAGTCTCGTTTCAGCTTATTTAATAATAAAAAACAC CCTTGTTTCTACT ) SEQ ID NO: 170 - WSN_NS_46 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGTGACAAATAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 171 - WSN_NS_63 AGCAAAAGCAGGGTGACACTCGTTTCAGCTTATTTAATAATAAAAAACACCCTT GTTTCTACT ) SEQ ID NO: 172 - WSN_NP_94 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCGAC CAAAGGCACCAAACGATCTTACAAATACCCTTGTTTCTACT ) SEQ ID NO: 173 - WSN_NP_71 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCAAA AATACCCTTGTTTCTACT ) SEQ ID NO: 174 - WSN_NP_74 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCAAG AAAAATACCCTTGTTTCTACT ) SEQ ID NO: 175 - WSN_NP_76 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCTAA AGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 176 - WSN_NP_91 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGAGAG GAGTACGACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 177 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATAAAATACCC TTGTTTCTACT ) SEQ ID NO: 178 - WSN_NP_65 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAAGAAAAATACC CTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 179 - WSN_NP_63 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAGAAAAATACCCT TGTTTCTACT ) SEQ ID NO: 180 - WSN_NP_88 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGCAATGCAGAGGAG TACGACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 181 - WSN_NP_60 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAAAAATACCCTTGTT TCTACT ) SEQ ID NO: 182 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAAAGAAAAATACCC TTGTTTCTACT ) SEQ ID NO: 183 - WSN_NP_84 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATATGCAGAGGAGTACG ACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 184 - WSN_NP_59 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACAGAAAAATACCCTTGTT TCTACT ) SEQ ID NO: 185 - WSN_NP_71 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACAACGACAATTAAAGAAA AATACCCTTGTTTCTACT ) SEQ ID NO: 186 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGAAATTAAAGAAAAATACCC TTGTTTCTACT ) SEQ ID NO: 187 - WSN_NP_71 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGAGTACGACAATTAAAGAAA AATACCCTTGTTTCTACT ) SEQ ID NO: 188 - WSN_NP_63 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTCAATTAAAGAAAAATACCCT TGTTTCTACT ) SEQ ID NO: 189 - WSN_NP_50 AGCAAAAGCAGGGTAGATAATCACTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 190 - WSN_NP_62 AGCAAAAGCAGGGTAGATAATCACGAGTACGACAATTAAAGAAAAATACCCTT GTTTCTACT ) SEQ ID NO: 191 - WSN_NP_45 AGCAAAAGCAGGGTAGATAATCAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 192 - WSN_NP_50 AGCAAAAGCAGGGTAGATAATCATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 193 - WSN_NP_42 AGCAAAAGCAGGGTAGATAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 194 - WSN_NP_46 AGCAAAAGCAGGGTAGATATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 195 - WSN_NP_46 AGCAAAAGCAGGGTAGAAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 196 - WSN_NA_86 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAATAATAACCATTGGaTC gATCTGTATGCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 197 - WSN_NA_64 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAATAATAACAAAACTCC TTGTTTCTACT ) SEQ ID NO: 198 - WSN_NA_66 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGATAGTTTGTTCAAAAAACTC CTTGTTTCTACT ) SEQ ID NO: 199 - WSN_NA_67 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAAAGTAGTTTGTTCAAAAAAC TCCTTGTTTCTACT ) SEQ ID NO: 200 - WSN_NA_68 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCACAAGTAGTTTGTTCAAAAAA CTCCTTGTTTCTACT ) SEQ ID NO: 201 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAACAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT ) SEQ ID NO: 202 - WSN_NA_72 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCATTGACAAGTAGTTTGTTCAAA AAACTCCTTGTTTCTACT ) SEQ ID NO: 203 - WSN_NA_63 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 204 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCGACAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT ) SEQ ID NO: 205 - WSN_NA_65 AGCAAAAGCAGGAGTTTAAATGAATCCAAACAAGTAGTTTGTTCAAAAAACTCC TTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 206 - WSN_NA_66 AGCAAAAGCAGGAGTTTAAATGAATCCAAAACAAGTAGTTTGTTCAAAAAACT CCTTGTTTCTACT ) SEQ ID NO: 207 - WSN_NA_67 AGCAAAAGCAGGAGTTTAAATGAATCCAAAGACAAGTAGTTTGTTCAAAAAAC TCCTTGTTTCTACT ) SEQ ID NO: 208 - WSN_NA_68 AGCAAAAGCAGGAGTTTAAATGAATCCAAATGACAAGTAGTTTGTTCAAAAAA CTCCTTGTTTCTACT ) SEQ ID NO: 209 - WSN_NA_65 AGCAAAAGCAGGAGTTTAAATGAATCCAGACAAGTAGTTTGTTCAAAAAACTCC TTGTTTCTACT ) SEQ ID NO: 210 - WSN_NA_68 AGCAAAAGCAGGAGTTTAAATGAATCCCATTGACAAGTAGTTTGTTCAAAAAAC TCCTTGTTTCTACT ) SEQ ID NO: 211 - WSN_NA_55 AGCAAAAGCAGGAGTTTAAATGAGTAGTTTGTTCAAAAAACTCCTTGTTTCTAC ) SEQ ID NO: 212 - WSN_NA_63 AGCAAAAGCAGGAGTTTAAATGCATTGACAAGTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 213 - WSN_NA_49 AGCAAAAGCAGGAGTTTAAATTTTGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 214 - WSN_NA_56 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGAGTTTAAATCAAGTAGTTTGTTCAAAAAACTCCTTGTTTCTA CT ) SEQ ID NO: 215 - WSN_NA_43 AGCAAAAGCAGGAGTTTAATTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 216 - WSN_NA_62 AGCAAAAGCAGGAGTTTACACCATTGACAAGTAGTTTGTTCAAAAAACTCCTTG TTTCTACT ) SEQ ID NO: 217 - WSN_M_78 AGCGAAAGCAGGTAGATATTGAAAGATGAGTCTTCTAACCGAGGTCGAAACGG AGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 218 - WSN_M_61 AGCGAAAGCAGGTAGATATTGAAAGATTAGAGCTGGAGTAAAAAACTACCTTG TTTCTACT ) SEQ ID NO: 219 - WSN_M_50 AGCGAAAGCAGGTAGATATTGAAAGATTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 220 - WSN_M_43 AGCGAAAGCAGGTAGATATTTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 221 - WSN_M_46 AGCGAAAGCAGGTAGATATGGAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 222 - WSN_HA_77 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGTAGGATTTCAGAAATATA AGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 223 - WSN_HA_53 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 224 - WSN_HA_61 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATATAAGGAAAAACACCCTT GTTTCTACT ) SEQ ID NO: 225 - WSN_HA_65 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATAAATATAAGGAAAAACAC CCTTGTTTCTACT ) SEQ ID NO: 226 - WSN_HA_60 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAAATAAGGAAAAACACCCTTG TTTCTACT ) SEQ ID NO: 227 - WSN_HA_87 AGCAAAAGCAGGGGAAAATAAAAACAACCAATATGCATCTGAGATTAGGATTT CAGAAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 228 - WSN_HA_65 AGCAAAAGCAGGGGAAAATAAAAACAACCATCAGAAATATAAGGAAAAACAC CCTTGTTTCTACT ) SEQ ID NO: 229 - WSN_HA_66 AGCAAAAGCAGGGGAAAATAAAAACAACCATTCAGAAATATAAGGAAAAACA CCCTTGTTTCTACT ) SEQ ID NO: 230 - WSN_HA_51 AGCAAAAGCAGGGGAAAATAAAAACAACCGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 231 - WSN_HA_50 AGCAAAAGCAGGGGAAAATAAAAACAACGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 232 - WSN_HA_46 AGCAAAAGCAGGGGAAAATAAAAACAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 233 - WSN_HA_65 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGGAAAATAAAAACAGATTTCAGAAATATAAGGAAAAACAC CCTTGTTTCTACT ) SEQ ID NO: 234 - WSN_HA_44 AGCAAAAGCAGGGGAAAATAAAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 235 - WSN_HA_56 AGCAAAAGCAGGGGAAAATAAAAAGAAATATAAGGAAAAACACCCTTGTTTCT ACT ) SEQ ID NO: 236 - WSN_HA_60 AGCAAAAGCAGGGGAAAATAAAAATTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 237 - WSN_HA_63 AGCAAAAGCAGGGGAAAATAAAAAGATTTCAGAAATATAAGGAAAAACACCCT TGTTTCTACT ) SEQ ID NO: 238 - WSN_HA_44 AGCAAAAGCAGGGGAAAATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 239 - WSN_HA_60 AGCAAAAGCAGGGGAAAATAGGATTTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 240 - WSN_HA_53 AGCAAAAGCAGGGGAAAATCAGAAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 241 - WSN_HA_58 AGCAAAAGCAGGGGAAAATGATTTCAGAAATATAAGGAAAAACACCCTTGTTT CTACT ) SEQ ID NO: 242 - WSN_HA_41 AGCAAAAGCAGGGGAAAAGGAAAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 213) SEQ ID NO: 243 - WSN_HA_43 AGCAAAAGCAGGGGAAAAAAGGAAAAACACCCTTGTTTCTACT 214) SEQ ID NO: 244 - WSN_HA_50 AGCAAAAGCAGGGGAAAAGAAATATAAGGAAAAACACCCTTGTTTCTACT 215) SEQ ID NO: 245 - WSN_HA_64 AGCAAAAGCAGGGGAAAAAGATTAGGATTTCAGAAATATAAGGAAAAACACCC TTGTTTCTACT Example 3: Fasta file 2. WSN mvRNA sequences. 1) SEQ ID NO: 246 - WSN_NP_61 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATAGAAAAATACCCTTG TTTCTACT 2) SEQ ID NO: 247 - WSN_PB1_57 AGCGAAAGCAGGCAAACCATTTGAATGGATTTCATGAAAAAATGCCTTGTTTCT ACT 3) SEQ ID NO: 248 - WSN_PB1_57 AGCGAAAGCAGGCAAACCATTTGAATGTCCTTCATGAAAAAATGCCTTGTTTCT ACT 4) SEQ ID NO: 249 - WSN_PB1_62 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAAATGCCTTG TTTCTACT 5) SEQ ID NO: 250 - WSN_PB1_66 AGCGAAAGCAGGCAAACCATTTGAATGTTTAGCTTGTCCTTCATGAAAAAATGC CTTGTTTCTACT 6) SEQ ID NO: 251 - WSN_NP_58 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAAATACCCTTGTTTC TACT ) SEQ ID NO: 252 - WSN_HA_60 AGCAAAAGCAGGGGAAATTAGGATTTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 253 - WSN_HA_44 AGCAAAAGCAGGGGAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 254 - WSN_PB1_69 AGCGAAAGCAGGCAAACCATTTGAATGGATGTTAGCTTGTCCTTCATGAAAAAA TGCCTTGTTTCTACT 0) SEQ ID NO: 255 - WSN_PB1_61 AGCGAAAGCAGGCAAACCATTTGAATGGTTGTCCTTCATGAAAAAATGCCTTGT TTCTACT 1) SEQ ID NO: 256 - WSN_NP_63 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACTTAAAGAAAAATACCCT TGTTTCTACT 2) SEQ ID NO: 257 - WSN_NA_70 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCTGACAAGTAGTTTGTTCAAAA AACTCCTTGTTTCTACT 3) SEQ ID NO: 258 - WSN_NA_62 AGCAAAAGCAGGAGTTTACACCATTGACAAGTAGTTTGTTCAAAAAACTCCTTG TTTCTACT 4) SEQ ID NO: 259 - WSN_PB1_65 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTGAAAAAATGC CTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 260 - WSN_PB1_69 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGTCCTTCATGAAAAAA TGCCTTGTTTCTACT ) SEQ ID NO: 261 - WSN_PB1_48 AGCGAAAGCAGGCAAACCATTTGAATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 262 - WSN_PB1_62 AGCGAAAGCAGGCAAACCATTTGAATAGCTTGTCCTTCATGAAAAAATGCCTTG TTTCTACT ) SEQ ID NO: 263 - WSN_NP_71 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCAAA AATACCCTTGTTTCTACT ) SEQ ID NO: 264 - WSN_NP_76 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATCATGGCTAA AGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 265 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGAAATAAAATACCC TTGTTTCTACT ) SEQ ID NO: 266 - WSN_NP_55 AGCAAAAGCAGGGTAGATAATCACTCACAGAGAGAAAAATACCCTTGTTTCTAC T ) SEQ ID NO: 267 - WSN_NP_44 AGCAAAAGCAGGGTAGATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 268 - WSN_HA_58 AGCAAAAGCAGGGGAATAGGATTTCAGAAATATAAGGAAAAACACCCTTGTTT CTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 269 - WSN_HA_64 AGCAAAAGCAGGGGAATGAGATTAGGATTTCAGAAATATAAGGAAAAACACCC TTGTTTCTACT ) SEQ ID NO: 270 - WSN_PB2_80 AGCGAAAGCAGGTCAATTATATTCAATATGGAAGGCCATCAATTAGTGTCGAAT AGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 271 - WSN_PB1_77 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTTTTCTCA TGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 272 - WSN_PB1_65 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACAAAATGCC TTGTTTCTACT ) SEQ ID NO: 273 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTAAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 274 - WSN_PB1_68 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTCATGAAAAAA TGCCTTGTTTCTACT ) SEQ ID NO: 275 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTGAAAAAATGCC TTGTTTCTACT ) SEQ ID NO: 276 - WSN_PB1_58 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCAAAAATGCCTTGTTTC TACT ) SEQ ID NO: 277 - WSN_PB1_64 Attorney Docket No.11676-003WO1 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCTCATGAAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 278 - WSN_PB1_68 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCCTCCTTCATGAAAAAAT GCCTTGTTTCTACT ) SEQ ID NO: 279 - WSN_PB1_60 AGCGAAAGCAGGCAAACCATTTGAATGGATGTCAATCTGAAAAAATGCCTTGTT TCTACT ) SEQ ID NO: 280 - WSN_PB1_54 AGCGAAAGCAGGCAAACCATTTGAATGGATGTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 281 - WSN_PB1_50 AGCGAAAGCAGGCAAACCATTTGAATGGGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 282 - WSN_PB1_66 AGCGAAAGCAGGCAAACCATTTGAATGGTTAGCTTGTCCTTCATGAAAAAATGC CTTGTTTCTACT ) SEQ ID NO: 283 - WSN_PB1_49 AGCGAAAGCAGGCAAACCATTTGAATTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 284 - WSN_PB1_48 AGCGAAAGCAGGCAAACCATTTGCATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 285 - WSN_PB1_43 AGCGAAAGCAGGCAAACCATTTAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 286 - WSN_PB1_64 AGCGAAAGCAGGCAAACCATGTGAATTTAGCTTGTCCTTCATGAAAAAATGCCT TGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 287 - WSN_PB1_61 AGCGAAAGCAGGCAAACCTGAATTTAGCTTGTCCTTCATGAAAAAATGCCTTGT TTCTACT ) SEQ ID NO: 288 - WSN_PB1_40 AGCGAAAGCAGGCAAACTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 289 - WSN_PB1_56 AGCGAAAGCAGGCAAACTTTAGCTTGTCCTTCATGAAAAAATGCCTTGTTTCTA CT ) SEQ ID NO: 290 - WSN_PA_60 AGCGAAAGCAGGTACTGATTCAAAATGGCATACTGTCCAAAAAAGTACCTTGTT TCTACT ) SEQ ID NO: 291 - WSN_PA_66 AGCGAAAGCAGGTACTGATTCAAAATGTGCTATCCATACTGTCCAAAAAAGTAC CTTGTTTCTACT ) SEQ ID NO: 292 - WSN_NS_80 AGCAAAAGCAGGGTGACAAAGACATAATGGATCCAAACACTGTGTCAAGCTTT CAGATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 293 - WSN_NS_56 AGCAAAAGCAGGGTGACAAAGACATAATGGATCTAAAAAACACCCTTGTTTCT ACT ) SEQ ID NO: 294 - WSN_NS_55 AGCAAAAGCAGGGTGACAAAGACATAATGTAATAAAAAACACCCTTGTTTCTA CT ) SEQ ID NO: 295 - WSN_NP_66 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCGTAAAGAAAAATAC CCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 296 - WSN_NP_60 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCAAAAATACCCTTGTT TCTACT ) SEQ ID NO: 297 - WSN_NP_65 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTAAAGAAAAATACC CTTGTTTCTACT ) SEQ ID NO: 298 - WSN_NP_66 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTTAAAGAAAAATAC CCTTGTTTCTACT ) SEQ ID NO: 299 - WSN_NP_74 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATCTACGACAATTAAAG AAAAATACCCTTGTTTCTACT ) SEQ ID NO: 300 - WSN_NP_64 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACATTAAAGAAAAATACCC TTGTTTCTACT ) SEQ ID NO: 301 - WSN_NP_59 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACAGAAAAATACCCTTGTT TCTACT ) SEQ ID NO: 302 - WSN_NP_72 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGACGTACGACAATTAAAGAA AAATACCCTTGTTTCTACT ) SEQ ID NO: 303 - WSN_NP_70 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTGATACGACAATTAAAGAAAA ATACCCTTGTTTCTACT ) SEQ ID NO: 304 - WSN_NP_57 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGGTAGATAATCACTCACAGAGTAAGAAAAATACCCTTGTTTCT ACT ) SEQ ID NO: 305 - WSN_NP_44 AGCAAAAGCAGGGTAGATAATCACTAAATACCCTTGTTTCTACT ) SEQ ID NO: 306 - WSN_NP_49 AGCAAAAGCAGGGTAGATAATCACTAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 307 - WSN_NP_43 AGCAAAAGCAGGGTAGTTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 308 - WSN_NA_75 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAATAAAAGTAGTTTGTT CAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 309 - WSN_NA_73 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAACAAGTAGTTTGTTCA AAAAACTCCTTGTTTCTACT ) SEQ ID NO: 310 - WSN_NA_79 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAACATTGACAAGTAGTT TGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 311 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGAAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT ) SEQ ID NO: 312 - WSN_NA_61 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGATGTTCAAAAAACTCCTTGT TTCTACT ) SEQ ID NO: 313 - WSN_NA_60 Attorney Docket No.11676-003WO1 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAGTGTTCAAAAAACTCCTTGTT TCTACT ) SEQ ID NO: 314 - WSN_NA_69 AGCAAAAGCAGGAGTTTAAATGAATCCAAACCAACAAGTAGTTTGTTCAAAAA ACTCCTTGTTTCTACT ) SEQ ID NO: 315 - WSN_NA_66 AGCAAAAGCAGGAGTTTAAATGAATCCAAAACAAGTAGTTTGTTCAAAAAACT CCTTGTTTCTACT ) SEQ ID NO: 316 - WSN_NA_60 AGCAAAAGCAGGAGTTTAAATGAATCCAATAGTTTGTTCAAAAAACTCCTTGTT TCTACT ) SEQ ID NO: 317 - WSN_NA_63 AGCAAAAGCAGGAGTTTAACACCATTGACAAGTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 318 - WSN_NA_62 AGCAAAAGCAGGAGTTTTCACCATTGACAAGTAGTTTGTTCAAAAAACTCCTTG TTTCTACT ) SEQ ID NO: 319 - WSN_NA_63 AGCAAAAGCAGGAGTCGTTCACCATTGACAAGTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 320 - WSN_M_71 AGCGAAAGCAGGTAGATATTGAAAGATGAGTCTTCCATAGAGCTGGAGTAAAA AACTACCTTGTTTCTACT ) SEQ ID NO: 321 - WSN_M_52 AGCGAAAGCAGGTAGATATTGAAAGATGAGAAAAAACTACCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 322 - WSN_M_48 AGCGAAAGCAGGTAGATATTGAAAGATAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 323 - WSN_M_47 AGCGAAAGCAGGTAGATATTGAAATAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 324 - WSN_HA_89 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCAGATTAGGATTTC AGAAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 325 - WSN_HA_90 AGCAAAAGCAGGGGAAAATAAAAACAACCAAAATGAAGGCCTGAGATTAGGA TTTCAGAAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 326 - WSN_HA_50 AGCAAAAGCAGGGGAAAATAAAAACAACGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 327 - WSN_HA_63 AGCAAAAGCAGGGGAAAATAAAAACATTTCAGAAATATAAGGAAAAACACCCT TGTTTCTACT ) SEQ ID NO: 328 - WSN_HA_44 AGCAAAAGCAGGGGAAAATAAAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 329 - WSN_HA_41 AGCAAAAGCAGGGGAAAATGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 330 - WSN_HA_65 AGCAAAAGCAGGGGAAATGAGATTAGGATTTCAGAAATATAAGGAAAAACACC CTTGTTTCTACT ) SEQ ID NO: 331 - WSN_HA_66 AGCAAAAGCAGGGGAAACTGAGATTAGGATTTCAGAAATATAAGGAAAAACAC CCTTGTTTCTACT Attorney Docket No.11676-003WO1 87) SEQ ID NO: 332 - WSN_HA_61 AGCAAAAGCAGGGGAAGATTAGGATTTCAGAAATATAAGGAAAAACACCCTTG TTTCTACT Example 4: Fasta file 3. WSN mvRNA sequences. 1) SEQ ID NO: 333 - BM18_PB2,1,2325,35:(18+17) AGCRAAAGCAGGTCAATTACGACCTTGTTTCTACT 2) SEQ ID NO: 334 - BM18_M,1,1009,36:(17+19) AGCRAAAGCAGGTAGATAAACTACCTTGTTTCTACT 3) SEQ ID NO: 335 - BM18_M,1,1010,35:(17+18) AGCRAAAGCAGGTAGATAACTACCTTGTTTCTACT 4) SEQ ID NO: 336 - BM18_PB2,1,2324,36:(18+18) AGCRAAAGCAGGTCAATTAACGACCTTGTTTCTACT 5) SEQ ID NO: 337 - BM18_NS,1,872,36:(17+19) AGCRAAAGCAGGGTGACAAACACCCTTGTTTCTACT 6) SEQ ID NO: 338 - BM18_NP,1,1547,37:(18+19) AGCRAAAGCAGGGTAGATAAATACCCTTGTTTCTACT 7) SEQ ID NO: 339 - BM18_HA,1,1762,36:(19+17) AGCRAAAGCAGGGGAAAATACACCCTTGTTTCTACT 8) SEQ ID NO: 340 - BM18_NP,1,1541,41:(16+25) AGCRAAAGCAGGGTAGAAAGAAAAATACCCTTGTTTCTACT 9) SEQ ID NO: 341 - BM18_NP,1,1547,35:(16+19) AGCRAAAGCAGGGTAGAAATACCCTTGTTTCTACT 10) SEQ ID NO: 342 - BM18_PB2,1,2323,37:(18+19) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGTCAATTAAACGACCTTGTTTCTACT ) SEQ ID NO: 343 - BM18_PB2,1,2319,39:(16+23) AGCRAAAGCAGGTCAATTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 344 - BM18_HA,1,1761,37:(19+18) AGCRAAAGCAGGGGAAAATAACACCCTTGTTTCTACT ) SEQ ID NO: 345 - BM18_NS,1,869,39:(17+22) AGCRAAAGCAGGGTGACAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 346 - BM18_NP,1,1545,39:(18+21) AGCRAAAGCAGGGTAGATAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 347 - BM18_NP,1,1548,34:(16+18) AGCRAAAGCAGGGTAGAATACCCTTGTTTCTACT ) SEQ ID NO: 348 - BM18_M,1,1008,37:(17+20) AGCRAAAGCAGGTAGATAAAACTACCTTGTTTCTACT ) SEQ ID NO: 349 - BM18_NS,1,871,37:(17+20) AGCRAAAGCAGGGTGACAAAACACCCTTGTTTCTACT ) SEQ ID NO: 350 - BM18_NS,1,873,35:(17+18) AGCRAAAGCAGGGTGACAACACCCTTGTTTCTACT ) SEQ ID NO: 351 - BM18_HA,1,1760,38:(19+19) AGCRAAAGCAGGGGAAAATAAACACCCTTGTTTCTACT ) SEQ ID NO: 352 - BM18_HA,1,1752,44:(17+27) AGCRAAAGCAGGGGAAAATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 353 - BM18_NP,1,1546,36:(16+20) AGCRAAAGCAGGGTAGAAAATACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 354 - BM18_M,1,1005,39:(16+23) AGCRAAAGCAGGTAGATAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 355 - BM18_NP,1,1546,38:(18+20) AGCRAAAGCAGGGTAGATAAAATACCCTTGTTTCTACT ) SEQ ID NO: 356 - BM18_PB1,1,2324,36:(18+18) AGCRAAAGCAGGCAAACCAAATGCCTTGTTTCTACT ) SEQ ID NO: 357 - BM18_HA,1,1757,41:(19+22) AGCRAAAGCAGGGGAAAATGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 358 - BM18_NP,1,1540,43:(17+26) AGCRAAAGCAGGGTAGATAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 359 - BM18_NP,1,1544,38:(16+22) AGCRAAAGCAGGGTAGGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 360 - BM18_PB1,1,2323,37:(18+19) AGCRAAAGCAGGCAAACCAAAATGCCTTGTTTCTACT ) SEQ ID NO: 361 - BM18_HA,1,1758,37:(16+21) AGCRAAAGCAGGGGAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 362 - BM18_NP,1,1549,35:(18+17) AGCRAAAGCAGGGTAGATATACCCTTGTTTCTACT ) SEQ ID NO: 363 - BM18_PB2,1,2322,38:(18+20) AGCRAAAGCAGGTCAATTAAAACGACCTTGTTTCTACT ) SEQ ID NO: 364 - BM18_M,1,1011,34:(17+17) AGCRAAAGCAGGTAGATACTACCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 365 - BM18_HA,1,1759,39:(19+20) AGCRAAAGCAGGGGAAAATAAAACACCCTTGTTTCTACT ) SEQ ID NO: 366 - BM18_PB2,1,2315,44:(17+27) AGCRAAAGCAGGTCAATTAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 367 - BM18_NP,1,1543,39:(16+23) AGCRAAAGCAGGGTAGAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 368 - BM18_HA,1,1758,38:(17+21) AGCRAAAGCAGGGGAAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 369 - BM18_HA,1,1754,42:(17+25) AGCRAAAGCAGGGGAAAAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 370 - BM18_PB1,1,2325,35:(18+17) AGCRAAAGCAGGCAAACCAATGCCTTGTTTCTACT ) SEQ ID NO:371 - BM18_NS,1,867,47:(23+24) AGCRAAAGCAGGGTGACAAAGACATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 372 - BM18_NS,1,870,38:(17+21) AGCRAAAGCAGGGTGACAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 373: BM18_NS,1,874,34:(17+17) AGCRAAAGCAGGGTGACACACCCTTGTTTCTACT ) SEQ ID NO: 374 - BM18_PB1,1,2321,39:(18+21) AGCRAAAGCAGGCAAACCAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 375 - BM18_M,1,1007,38:(17+21) AGCRAAAGCAGGTAGATAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 376 - BM18_HA,1,1756,42:(19+23) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGGAAAATGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 377 - BM18_NA,1,1439,36:(17+19) AGCRAAAGCAGGAGTTTAAAACTCCTTGTTTCTACT ) SEQ ID NO: 378 - BM18_PB1,1,2322,38:(18+20) AGCRAAAGCAGGCAAACCAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 379 - BM18_M,1,1004,41:(17+24) AGCRAAAGCAGGTAGATGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 380 - BM18_NP,1,1544,40:(18+22) AGCRAAAGCAGGGTAGATGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 381 - BM18_NP,1,1542,40:(16+24) AGCRAAAGCAGGGTAGAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 382 - BM18_HA,1,1754,41:(16+25) AGCRAAAGCAGGGGAAAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 383 - BM18_PB2,1,2313,47:(18+29) AGCRAAAGCAGGTCAATTAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 384 - BM18_M,1,1005,42:(19+23) AGCRAAAGCAGGTAGATGTTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 385 - BM18_NP,1,1543,41:(18+23) AGCRAAAGCAGGGTAGATAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 386 - BM18_PB2,1,2313,53:(24+29) AGCRAAAGCAGGTCAATTATATTCAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 387 - BM18_PB2,1,2314,46:(18+28) AGCRAAAGCAGGTCAATTATAGTTTAAAAACGACCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 388 - BM18_PB1,1,2322,43:(23+20) AGCRAAAGCAGGCAAACCATTTGAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 389 - BM18_PB1,1,2319,44:(21+23) AGCRAAAGCAGGCAAACCATTTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 390 - BM18_M,1,1006,43:(21+22) AGCRAAAGCAGGTAGATGTTGAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 391 - BM18_PA,1,2212,48:(26+22) AGCRAAAGCAGGTACTGATTCAAAATAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 392 - BM18_PA,1,2216,39:(21+18) AGCRAAAGCAGGTACTGATTCAAGTACCTTGTTTCTACT ) SEQ ID NO: 393 - BM18_PA,1,2216,34:(16+18) AGCRAAAGCAGGTACTAAGTACCTTGTTTCTACT ) SEQ ID NO: 394 - BM18_PA,1,2215,35:(16+19) AGCRAAAGCAGGTACTAAAGTACCTTGTTTCTACT ) SEQ ID NO: 395 - BM18_PB2,1,2308,60:(26+34) AGCRAAAGCAGGTCAATTATATTCAATGTCGAATAGTTTAAAAACGACCTTGTT TCTACT ) SEQ ID NO: 396 - BM18_HA,1,1746,52:(19+33) AGCRAAAGCAGGGGAAAATAGAAATATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 397 - BM18_HA,1,1741,57:(19+38) AGCRAAAGCAGGGGAAAATATTTCAGAAATATAAGGAAAAACACCCTTGTTTCT ACT ) SEQ ID NO: 398 - BM18_HA,1,1758,39:(18+21) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGGAAAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 399 - BM18_HA,1,1737,60:(18+42) AGCRAAAGCAGGGGAAAATAGGATTTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 400 - BM18_NS,1,869,43:(21+22) AGCRAAAGCAGGGTGACAAAGAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 401 - BM18_M,1,1000,46:(18+28) AGCRAAAGCAGGTAGATGTGGAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 402 - BM18_NA,1,1409,66:(17+49) AGCRAAAGCAGGAGTTTCCATTCACCATTGACAAGTAGTTTGTTCAAAAAACTC CTTGTTTCTACT ) SEQ ID NO: 403 - BM18_NA,1,1423,51:(16+35) AGCRAAAGCAGGAGTTCAAGTAGTTTGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 404 - BM18_NP,1,1545,38:(17+21) AGCRAAAGCAGGGTAGAAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 405 - BM18_NP,1,1541,42:(17+25) AGCRAAAGCAGGGTAGAAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 406 - BM18_PA,1,2207,52:(25+27) AGCRAAAGCAGGTACTGATTCAAAATGTCCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 407 - BM18_PA,1,2211,43:(20+23) AGCRAAAGCAGGTACTGATTCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 408 - BM18_PB1,1,2320,45:(23+22) AGCRAAAGCAGGCAAACCATTTGGAAAAAATGCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 409 - BM18_PB1,1,2302,58:(18+40) AGCRAAAGCAGGCAAACCATTTAGCTTGTCCTTCATGAAAAAATGCCTTGTTTC TACT ) SEQ ID NO: 410 - BM18_HA,1,1755,43:(19+24) AGCRAAAGCAGGGGAAAATAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 411 - BM18_HA,1,1757,38:(16+22) AGCRAAAGCAGGGGAAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 412 - BM18_NS,1,864,50:(23+27) AGCRAAAGCAGGGTGACAAAGACATAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 413 - BM18_NS,1,869,42:(20+22) AGCRAAAGCAGGGTGACAAAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 414 - BM18_M,1,988,73:(33+40) AGCRAAAGCAGGTAGATGTTGAAAGATGAGTCTTCAACATAGAGCTGGAGTAA AAAACTACCTTGTTTCTACT ) SEQ ID NO: 415 - BM18_NA,1,1428,62:(32+30) AGCRAAAGCAGGAGTTTAAATGAATCCAAATCAGTTTGTTCAAAAAACTCCTTG TTTCTACT ) SEQ ID NO: 416 - BM18_NA,1,1437,38:(17+21) AGCRAAAGCAGGAGTTTAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 417 - BM18_NP,1,1547,58:(39+19) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAATACCCTTGTTTC TACT ) SEQ ID NO: 418 - BM18_NP,1,1546,56:(36+20) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACAAAATACCCTTGTTTCTA CT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 419 - BM18_NP,1,1535,59:(28+31) AGCRAAAGCAGGGTAGATAATCACTCACACAATTAAAGAAAAATACCCTTGTTT CTACT ) SEQ ID NO: 420 - BM18_NP,1,1540,42:(16+26) AGCRAAAGCAGGGTAGTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 421 - BM18_PA,1,2213,42:(21+21) AGCRAAAGCAGGTACTGATTCAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 422 - BM18_PA,1,2216,35:(17+18) AGCRAAAGCAGGTACTGAAGTACCTTGTTTCTACT ) SEQ ID NO: 423 - BM18_PA,1,2217,33:(16+17) AGCRAAAGCAGGTACTAGTACCTTGTTTCTACT ) SEQ ID NO: 424 - BM18_PB2,1,2312,48:(18+30) AGCRAAAGCAGGTCAATTGAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 425 - BM18_PB2,1,2308,51:(17+34) AGCRAAAGCAGGTCAATTGTCGAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 426 - BM18_PB1,1,2296,71:(25+46) AGCRAAAGCAGGCAAACCATTTGAATAGTGAATTTAGCTTGTCCTTCATGAAAA AATGCCTTGTTTCTACT ) SEQ ID NO: 427 - BM18_PB1,1,2324,40:(22+18) AGCRAAAGCAGGCAAACCATTTAAATGCCTTGTTTCTACT ) SEQ ID NO: 428 - BM18_PB1,1,2321,43:(22+21) AGCRAAAGCAGGCAAACCATTTAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 429 - BM18_HA,1,1758,46:(25+21) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGGAAAATAAAAACAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 430 - BM18_HA,1,1746,55:(22+33) AGCRAAAGCAGGGGAAAATAAAAGAAATATAAGGAAAAACACCCTTGTTTCTA CT ) SEQ ID NO: 431 - BM18_HA,1,1731,66:(18+48) AGCRAAAGCAGGGGAAAATGAGATTAGGATTTCAGAAATATAAGGAAAAACAC CCTTGTTTCTACT 0) SEQ ID NO: 432 - BM18_HA,1,1757,39:(17+22) AGCRAAAGCAGGGGAAAGAAAAACACCCTTGTTTCTACT 1) SEQ ID NO: 433 - BM18_NS,1,873,43:(25+18) AGCRAAAGCAGGGTGACAAAGACATAACACCCTTGTTTCTACT 2) SEQ ID NO: 434 - BM18_NS,1,870,46:(25+21) AGCRAAAGCAGGGTGACAAAGACATAAAAACACCCTTGTTTCTACT 3) SEQ ID NO: 435 - BM18_NS,1,858,57:(24+33) AGCRAAAGCAGGGTGACAAAGACATATTTAATAATAAAAAACACCCTTGTTTCT ACT 4) SEQ ID NO: 436 - BM18_NS,1,872,42:(23+19) AGCRAAAGCAGGGTGACAAAGACAAACACCCTTGTTTCTACT 5) SEQ ID NO: 437 - BM18_NS,1,873,39:(21+18) AGCRAAAGCAGGGTGACAAAGAACACCCTTGTTTCTACT 6) SEQ ID NO: 438 - BM18_NS,1,863,49:(21+28) AGCRAAAGCAGGGTGACAAAGAATAATAAAAAACACCCTTGTTTCTACT 7) SEQ ID NO: 439 - BM18_NS,1,866,43:(18+25) AGCRAAAGCAGGGTGACAAATAAAAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 440 - BM18_NS,1,866,42:(17+25) AGCRAAAGCAGGGTGACAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 441 - BM18_M,1,1003,56:(31+25) AGCRAAAGCAGGTAGATGTTGAAAGATGAGTAGTAAAAAACTACCTTGTTTCTA CT ) SEQ ID NO: 442 - BM18_M,1,1008,48:(28+20) AGCRAAAGCAGGTAGATGTTGAAAGATGAAAACTACCTTGTTTCTACT ) SEQ ID NO: 443 - BM18_M,1,1006,50:(28+22) AGCRAAAGCAGGTAGATGTTGAAAGATGAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 444 - BM18_M,1,1005,49:(26+23) AGCRAAAGCAGGTAGATGTTGAAAGATAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 445 - BM18_M,1,1010,43:(25+18) AGCRAAAGCAGGTAGATGTTGAAAGAACTACCTTGTTTCTACT ) SEQ ID NO: 446 - BM18_M,1,1006,47:(25+22) AGCRAAAGCAGGTAGATGTTGAAAGAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 447 - BM18_M,1,1007,42:(21+21) AGCRAAAGCAGGTAGATGTTGAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 448 - BM18_M,1,1002,46:(20+26) AGCRAAAGCAGGTAGATGTTGAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 449 - BM18_M,1,1003,44:(19+25) AGCRAAAGCAGGTAGATGTAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 450 - BM18_M,1,1000,45:(17+28) AGCRAAAGCAGGTAGATTGGAGTAAAAAACTACCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 451 - BM18_M,1,1005,40:(17+23) AGCRAAAGCAGGTAGATTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 452 - BM18_NA,1,1426,64:(32+32) AGCRAAAGCAGGAGTTTAAATGAATCCAAATCGTAGTTTGTTCAAAAAACTCCT TGTTTCTACT ) SEQ ID NO: 453 - BM18_NA,1,1418,63:(23+40) AGCRAAAGCAGGAGTTTAAATGAATTGACAAGTAGTTTGTTCAAAAAACTCCTT GTTTCTACT ) SEQ ID NO: 454 - BM18_NA,1,1420,58:(20+38) AGCRAAAGCAGGAGTTTAAATGACAAGTAGTTTGTTCAAAAAACTCCTTGTTTC TACT ) SEQ ID NO: 455 - BM18_NA,1,1421,55:(18+37) AGCRAAAGCAGGAGTTTAGACAAGTAGTTTGTTCAAAAAACTCCTTGTTTCTAC T ) SEQ ID NO: 456 - BM18_NA,1,1438,37:(17+20) AGCRAAAGCAGGAGTTTAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 457 - BM18_NP,1,1548,57:(39+18) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAATACCCTTGTTTCT ACT ) SEQ ID NO: 458 - BM18_NP,1,1545,60:(39+21) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAAATACCCTTGTT TCTACT ) SEQ ID NO: 459 - BM18_NP,1,1547,57:(38+19) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATAAATACCCTTGTTTCT ACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 460 - BM18_NP,1,1535,67:(36+31) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACACAATTAAAGAAAAATA CCCTTGTTTCTACT ) SEQ ID NO: 461 - BM18_NP,1,1548,39:(21+18) AGCRAAAGCAGGGTAGATAATAATACCCTTGTTTCTACT ) SEQ ID NO: 462 - BM18_NP,1,1542,42:(18+24) AGCRAAAGCAGGGTAGATAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 463 - BM18_NP,1,1537,47:(18+29) AGCRAAAGCAGGGTAGATAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 464 - BM18_NP,1,1535,49:(18+31) AGCRAAAGCAGGGTAGATACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 465 - BM18_NP,1,1520,62:(16+46) AGCRAAAGCAGGGTAGATGCAGAGGAGTACGACAATTAAAGAAAAATACCCTT GTTTCTACT ) SEQ ID NO: 466 - BM18_PA,1,2216,56:(38+18) AGCRAAAGCAGGTACTGATTCAAAATGGAAGACTTTGTAAGTACCTTGTTTCTA CT ) SEQ ID NO: 467 - BM18_PA,1,2216,54:(36+18) AGCRAAAGCAGGTACTGATTCAAAATGGAAGACTTTAAGTACCTTGTTTCTACT ) SEQ ID NO: 468 - BM18_PA,1,2198,61:(25+36) AGCRAAAGCAGGTACTGATTCAAAATATCCATACTGTCCAAAAAAGTACCTTGT TTCTACT ) SEQ ID NO: 469 - BM18_PA,1,2215,40:(21+19) AGCRAAAGCAGGTACTGATTCAAAGTACCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 470 - BM18_PA,1,2209,43:(18+25) AGCRAAAGCAGGTACTGATCCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 471 - BM18_PA,1,2212,39:(17+22) AGCRAAAGCAGGTACTGAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 472 - BM18_PB2,1,2312,64:(34+30) AGCRAAAGCAGGTCAATTATATTCAATATGGAAAGAATAGTTTAAAAACGACCT TGTTTCTACT ) SEQ ID NO: 473 - BM18_PB2,1,2313,56:(27+29) AGCRAAAGCAGGTCAATTATATTCAATAATAGTTTAAAAACGACCTTGTTTCTA CT ) SEQ ID NO: 474 - BM18_PB2,1,2320,48:(26+22) AGCRAAAGCAGGTCAATTATATTCAATAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 475 - BM18_PB2,1,2305,63:(26+37) AGCRAAAGCAGGTCAATTATATTCAATAGTGTCGAATAGTTTAAAAACGACCTT GTTTCTACT ) SEQ ID NO: 476 - BM18_PB2,1,2321,45:(24+21) AGCRAAAGCAGGTCAATTATATTCAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 477 - BM18_PB2,1,2316,50:(24+26) AGCRAAAGCAGGTCAATTATATTCAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 478 - BM18_PB2,1,2320,41:(19+22) AGCRAAAGCAGGTCAATTATAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 479 - BM18_PB2,1,2293,67:(18+49) AGCRAAAGCAGGTCAATTATGGCCATCAATTAGTGTCGAATAGTTTAAAAACGA CCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 480 - BM18_PB2,1,2324,35:(17+18) AGCRAAAGCAGGTCAATAACGACCTTGTTTCTACT ) SEQ ID NO: 481 - BM18_PB1,1,2319,75:(52+23) AGCRAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTTTTCTTG AAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 482 - BM18_PB1,1,2324,62:(44+18) AGCRAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTAAATGCCTTG TTTCTACT ) SEQ ID NO: 483 - BM18_PB1,1,2309,75:(42+33) AGCRAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTGTCCTTCATG AAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 484 - BM18_PB1,1,2324,48:(30+18) AGCRAAAGCAGGCAAACCATTTGAATGGATAAATGCCTTGTTTCTACT ) SEQ ID NO: 485 - BM18_PB1,1,2322,50:(30+20) AGCRAAAGCAGGCAAACCATTTGAATGGATAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 486 - BM18_PB1,1,2318,50:(26+24) AGCRAAAGCAGGCAAACCATTTGAATATGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 487 - BM18_PB1,1,2319,45:(22+23) AGCRAAAGCAGGCAAACCATTTTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 488 - BM18_PB1,1,2299,64:(21+43) AGCRAAAGCAGGCAAACCATTTGAATTTAGCTTGTCCTTCATGAAAAAATGCCT TGTTTCTACT ) SEQ ID NO: 489 - BM18_PB1,1,2309,53:(20+33) AGCRAAAGCAGGCAAACCATTTGTCCTTCATGAAAAAATGCCTTGTTTCTACT Attorney Docket No.11676-003WO1 158) SEQ ID NO: 490 - BM18_PB1,1,2320,40:(18+22) AGCRAAAGCAGGCAAACCGAAAAAATGCCTTGTTTCTACT 159) SEQ ID NO: 491 - BM18_PB1,1,2311,49:(18+31) AGCRAAAGCAGGCAAACCGTCCTTCATGAAAAAATGCCTTGTTTCTACT 160) SEQ ID NO: 492 - BM18_PB1,1,2297,63:(18+45) AGCRAAAGCAGGCAAACCAGTGAATTTAGCTTGTCCTTCATGAAAAAATGCCTT GTTTCTACT 161) SEQ ID NO: 493 - BM18_PB1,1,2317,42:(17+25) AGCRAAAGCAGGCAAACCATGAAAAAATGCCTTGTTTCTACT 162) SEQ ID NO: 494 - BM18_PB1,1,2290,69:(17+52) AGCRAAAGCAGGCAAACCAAAAGTAGTGAATTTAGCTTGTCCTTCATGAAAAA ATGCCTTGTTTCTACT Example 5: Fasta file 4. WSN mvRNA sequences. 1) SEQ ID NO: 495 - BM18_PB2,1,2325,35:(18+17) AGCRAAAGCAGGTCAATTACGACCTTGTTTCTACT 2) SEQ ID NO: 496 - BM18_M,1,1010,35:(17+18) AGCRAAAGCAGGTAGATAACTACCTTGTTTCTACT 3) SEQ ID NO: 497 - BM18_M,1,1009,36:(17+19) AGCRAAAGCAGGTAGATAAACTACCTTGTTTCTACT 4) SEQ ID NO: 498 - BM18_PB2,1,2324,36:(18+18) AGCRAAAGCAGGTCAATTAACGACCTTGTTTCTACT 5) SEQ ID NO: 499 - BM18_NS,1,872,36:(17+19) AGCRAAAGCAGGGTGACAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 500 - BM18_NP,1,1548,34:(16+18) AGCRAAAGCAGGGTAGAATACCCTTGTTTCTACT ) SEQ ID NO: 501 - BM18_NP,1,1547,37:(18+19) AGCRAAAGCAGGGTAGATAAATACCCTTGTTTCTACT ) SEQ ID NO: 502 - BM18_NP,1,1547,35:(16+19) AGCRAAAGCAGGGTAGAAATACCCTTGTTTCTACT ) SEQ ID NO: 503 - BM18_HA,1,1762,36:(19+17) AGCRAAAGCAGGGGAAAATACACCCTTGTTTCTACT 0) SEQ ID NO: 504 - BM18_NS,1,873,35:(17+18) AGCRAAAGCAGGGTGACAACACCCTTGTTTCTACT 1) SEQ ID NO: 505 - BM18_NP,1,1545,39:(18+21) AGCRAAAGCAGGGTAGATAAAAATACCCTTGTTTCTACT 2) SEQ ID NO: 506 - BM18_HA,1,1752,44:(17+27) AGCRAAAGCAGGGGAAAATAAGGAAAAACACCCTTGTTTCTACT 3) SEQ ID NO: 507 - BM18_PB2,1,2323,37:(18+19) AGCRAAAGCAGGTCAATTAAACGACCTTGTTTCTACT 4) SEQ ID NO: 508 - BM18_NS,1,871,37:(17+20) AGCRAAAGCAGGGTGACAAAACACCCTTGTTTCTACT 5) SEQ ID NO: 509 - BM18_HA,1,1761,37:(19+18) AGCRAAAGCAGGGGAAAATAACACCCTTGTTTCTACT 6) SEQ ID NO: 510 - BM18_NP,1,1546,36:(16+20) AGCRAAAGCAGGGTAGAAAATACCCTTGTTTCTACT 7) SEQ ID NO: 511 - BM18_HA,1,1757,41:(19+22) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGGAAAATGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 512 - BM18_NS,1,869,39:(17+22) AGCRAAAGCAGGGTGACAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 513 - BM18_NP,1,1546,38:(18+20) AGCRAAAGCAGGGTAGATAAAATACCCTTGTTTCTACT ) SEQ ID NO: 514 - BM18_PB2,1,2319,39:(16+23) AGCRAAAGCAGGTCAATTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 515 - BM18_M,1,1008,37:(17+20) AGCRAAAGCAGGTAGATAAAACTACCTTGTTTCTACT ) SEQ ID NO: 516 - BM18_HA,1,1760,38:(19+19) AGCRAAAGCAGGGGAAAATAAACACCCTTGTTTCTACT ) SEQ ID NO: 517 - BM18_NP,1,1540,43:(17+26) AGCRAAAGCAGGGTAGATAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 518 - BM18_M,1,1005,39:(16+23) AGCRAAAGCAGGTAGATAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 519 - BM18_PB1,1,2324,36:(18+18) AGCRAAAGCAGGCAAACCAAATGCCTTGTTTCTACT ) SEQ ID NO: 520 - BM18_NP,1,1544,40:(18+22) AGCRAAAGCAGGGTAGATGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 521 - BM18_NP,1,1549,35:(18+17) AGCRAAAGCAGGGTAGATATACCCTTGTTTCTACT ) SEQ ID NO: 522 - BM18_M,1,1011,34:(17+17) AGCRAAAGCAGGTAGATACTACCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 523 - BM18_PB1,1,2323,37:(18+19) AGCRAAAGCAGGCAAACCAAAATGCCTTGTTTCTACT ) SEQ ID NO: 524 - BM18_HA,1,1758,37:(16+21) AGCRAAAGCAGGGGAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 525 - BM18_NP,1,1543,41:(18+23) AGCRAAAGCAGGGTAGATAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 526 - BM18_NS,1,874,34:(17+17) AGCRAAAGCAGGGTGACACACCCTTGTTTCTACT ) SEQ ID NO: 527 - BM18_PA,1,2216,34:(16+18) AGCRAAAGCAGGTACTAAGTACCTTGTTTCTACT ) SEQ ID NO: 528 - BM18_HA,1,1756,42:(19+23) AGCRAAAGCAGGGGAAAATGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 529 - BM18_PB2,1,2315,44:(17+27) AGCRAAAGCAGGTCAATTAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 530 - BM18_NS,1,870,38:(17+21) AGCRAAAGCAGGGTGACAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 531 - BM18_PB2,1,2322,38:(18+20) AGCRAAAGCAGGTCAATTAAAACGACCTTGTTTCTACT ) SEQ ID NO: 532 - BM18_PB1,1,2325,35:(18+17) AGCRAAAGCAGGCAAACCAATGCCTTGTTTCTACT ) SEQ ID NO: 533 - BM18_HA,1,1758,38:(17+21) AGCRAAAGCAGGGGAAAAAAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 534 - BM18_HA,1,1754,42:(17+25) AGCRAAAGCAGGGGAAAAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 535 - BM18_HA,1,1759,39:(19+20) AGCRAAAGCAGGGGAAAATAAAACACCCTTGTTTCTACT ) SEQ ID NO: 536 - BM18_NA,1,1439,36:(17+19) AGCRAAAGCAGGAGTTTAAAACTCCTTGTTTCTACT ) SEQ ID NO: 537 - BM18_M,1,1007,38:(17+21) AGCRAAAGCAGGTAGATAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 538 - BM18_NA,1,1437,38:(17+21) AGCRAAAGCAGGAGTTTAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 539 - BM18_PB1,1,2321,39:(18+21) AGCRAAAGCAGGCAAACCAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 540 - BM18_NS,1,867,47:(23+24) AGCRAAAGCAGGGTGACAAAGACATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 541 - BM18_NP,1,1532,62:(28+34) AGCRAAAGCAGGGTAGATAATCACTCACACGACAATTAAAGAAAAATACCCTT GTTTCTACT ) SEQ ID NO: 542 - BM18_NP,1,1541,41:(16+25) AGCRAAAGCAGGGTAGAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 543 - BM18_PB1,1,2322,38:(18+20) AGCRAAAGCAGGCAAACCAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 544 - BM18_NP,1,1531,52:(17+35) AGCRAAAGCAGGGTAGATACGACAATTAAAGAAAAATACCCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 545 - BM18_PA,1,2212,48:(26+22) AGCRAAAGCAGGTACTGATTCAAAATAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 546 - BM18_HA,1,1752,59:(32+27) AGCRAAAGCAGGGGAAAATAAAAACAACCAAAATAAGGAAAAACACCCTTGTT TCTACT ) SEQ ID NO: 547 - BM18_HA,1,1754,41:(16+25) AGCRAAAGCAGGGGAAAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 548 - BM18_PA,1,2211,43:(20+23) AGCRAAAGCAGGTACTGATTCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 549 - BM18_HA,1,1755,43:(19+24) AGCRAAAGCAGGGGAAAATAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 550 - BM18_HA,1,1737,60:(18+42) AGCRAAAGCAGGGGAAAATAGGATTTCAGAAATATAAGGAAAAACACCCTTGT TTCTACT ) SEQ ID NO: 551 - BM18_PB2,1,2313,47:(18+29) AGCRAAAGCAGGTCAATTAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 552 - BM18_NS,1,864,50:(23+27) AGCRAAAGCAGGGTGACAAAGACATAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 553 - BM18_NP,1,1546,56:(36+20) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACAAAATACCCTTGTTTCTA CT ) SEQ ID NO: 554 - BM18_NP,1,1535,59:(28+31) AGCRAAAGCAGGGTAGATAATCACTCACACAATTAAAGAAAAATACCCTTGTTT CTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 555 - BM18_PA,1,2212,44:(22+22) AGCRAAAGCAGGTACTGATTCAAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 556 - BM18_PA,1,2215,40:(21+19) AGCRAAAGCAGGTACTGATTCAAAGTACCTTGTTTCTACT ) SEQ ID NO: 557 - BM18_PA,1,2208,47:(21+26) AGCRAAAGCAGGTACTGATTCGTCCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 558 - BM18_PA,1,2215,35:(16+19) AGCRAAAGCAGGTACTAAAGTACCTTGTTTCTACT ) SEQ ID NO: 559 - BM18_PB2,1,2313,53:(24+29) AGCRAAAGCAGGTCAATTATATTCAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 560 - BM18_PB2,1,2314,46:(18+28) AGCRAAAGCAGGTCAATTATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 561 - BM18_PB2,1,2323,36:(17+19) AGCRAAAGCAGGTCAATAAACGACCTTGTTTCTACT ) SEQ ID NO: 562 - BM18_HA,1,1748,61:(30+31) AGCRAAAGCAGGGGAAAATAAAAACAACCAAAATATAAGGAAAAACACCCTTG TTTCTACT ) SEQ ID NO: 563 - BM18_HA,1,1738,66:(25+41) AGCRAAAGCAGGGGAAAATAAAAACAGGATTTCAGAAATATAAGGAAAAACA CCCTTGTTTCTACT ) SEQ ID NO: 564 - BM18_HA,1,1758,39:(18+21) AGCRAAAGCAGGGGAAAAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 565 - BM18_HA,1,1757,39:(17+22) AGCRAAAGCAGGGGAAAGAAAAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 566 - BM18_HA,1,1738,58:(17+41) AGCRAAAGCAGGGGAAAAGGATTTCAGAAATATAAGGAAAAACACCCTTGTTT CTACT ) SEQ ID NO: 567 - BM18_NS,1,866,55:(30+25) AGCRAAAGCAGGGTGACAAAGACATAATGGAATAAAAAACACCCTTGTTTCTA CT ) SEQ ID NO: 568 - BM18_M,1,1011,35:(18+17) AGCRAAAGCAGGTAGATGACTACCTTGTTTCTACT ) SEQ ID NO: 569 - BM18_NA,1,1428,57:(27+30) AGCRAAAGCAGGAGTTTAAATGAATCCAGTTTGTTCAAAAAACTCCTTGTTTCT ACT ) SEQ ID NO: 570 - BM18_NA,1,1427,47:(16+31) AGCRAAAGCAGGAGTTTAGTTTGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 571 - BM18_NP,1,1548,57:(39+18) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAATACCCTTGTTTCT ACT ) SEQ ID NO: 572 - BM18_NP,1,1535,57:(26+31) AGCRAAAGCAGGGTAGATAATCACTCACAATTAAAGAAAAATACCCTTGTTTCT ACT ) SEQ ID NO: 573 - BM18_PA,1,2207,52:(25+27) AGCRAAAGCAGGTACTGATTCAAAATGTCCAAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 574 - BM18_PA,1,2215,36:(17+19) AGCRAAAGCAGGTACTGAAAGTACCTTGTTTCTACT ) SEQ ID NO: 575 - BM18_PA,1,2214,36:(16+20) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGTACTAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 576 - BM18_PB2,1,2320,48:(26+22) AGCRAAAGCAGGTCAATTATATTCAATAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 577 - BM18_PB1,1,2321,43:(22+21) AGCRAAAGCAGGCAAACCATTTAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 578 - BM18_PB1,1,2319,44:(21+23) AGCRAAAGCAGGCAAACCATTTGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 579 - BM18_PB1,1,2320,39:(17+22) AGCRAAAGCAGGCAAACGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 580 - BM18_HA,1,1752,45:(18+27) AGCRAAAGCAGGGGAAAAATAAGGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 581 - BM18_HA,1,1731,66:(18+48) AGCRAAAGCAGGGGAAAATGAGATTAGGATTTCAGAAATATAAGGAAAAACAC CCTTGTTTCTACT ) SEQ ID NO: 582 - BM18_NS,1,869,52:(30+22) AGCRAAAGCAGGGTGACAAAGACATAATGGAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 583 - BM18_NS,1,872,40:(21+19) AGCRAAAGCAGGGTGACAAAGAAACACCCTTGTTTCTACT ) SEQ ID NO: 584 - BM18_M,1,1004,41:(17+24) AGCRAAAGCAGGTAGATGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 585 - BM18_NA,1,1433,53:(28+25) AGCRAAAGCAGGAGTTTAAATGAATCCAGTTCAAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 586 - BM18_NP,1,1544,61:(39+22) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCGAAAAATACCCTTGT TTCTACT ) SEQ ID NO: 587 - BM18_NP,1,1550,37:(21+16) AGCRAAAGCAGGGTAGATAATTACCCTTGTTTCTACT ) SEQ ID NO: 588 - BM18_NP,1,1529,55:(18+37) AGCRAAAGCAGGGTAGATAGTACGACAATTAAAGAAAAATACCCTTGTTTCTAC T ) SEQ ID NO: 589 - BM18_NP,1,1544,38:(16+22) AGCRAAAGCAGGGTAGGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 590 - BM18_PA,1,2207,64:(37+27) AGCRAAAGCAGGTACTGATTCAAAATGGAAGACTTTGTGTCCAAAAAAGTACCT TGTTTCTACT ) SEQ ID NO: 591 - BM18_PA,1,2214,41:(21+20) AGCRAAAGCAGGTACTGATTCAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 592 - BM18_PA,1,2217,33:(16+17) AGCRAAAGCAGGTACTAGTACCTTGTTTCTACT ) SEQ ID NO: 593 - BM18_PB2,1,2324,35:(17+18) AGCRAAAGCAGGTCAATAACGACCTTGTTTCTACT 0) SEQ ID NO: 594 - BM18_PB1,1,2294,74:(26+48) AGCRAAAGCAGGCAAACCATTTGAATAGTAGTGAATTTAGCTTGTCCTTCATGA AAAAATGCCTTGTTTCTACT 1) SEQ ID NO: 595 - BM18_PB1,1,2326,36:(20+16) AGCRAAAGCAGGCAAACCATATGCCTTGTTTCTACT 2) SEQ ID NO: 596 - BM18_PB1,1,2320,40:(18+22) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGCAAACCGAAAAAATGCCTTGTTTCTACT ) SEQ ID NO: 597 - BM18_PB1,1,2324,35:(17+18) AGCRAAAGCAGGCAAACAAATGCCTTGTTTCTACT ) SEQ ID NO: 598 - BM18_PB1,1,2323,36:(17+19) AGCRAAAGCAGGCAAACAAAATGCCTTGTTTCTACT ) SEQ ID NO: 599 - BM18_HA,1,1737,75:(33+42) AGCRAAAGCAGGGGAAAATAAAAACAACCAAAATAGGATTTCAGAAATATAAG GAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 600 - BM18_HA,1,1757,43:(21+22) AGCRAAAGCAGGGGAAAATAAGAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 601 - BM18_NS,1,868,63:(40+23) AGCRAAAGCAGGGTGACAAAGACATAATGGATTCTAACACTAAAAAACACCCT TGTTTCTACT ) SEQ ID NO: 602 - BM18_NS,1,871,45:(25+20) AGCRAAAGCAGGGTGACAAAGACATAAAACACCCTTGTTTCTACT ) SEQ ID NO: 603 - BM18_NS,1,862,53:(24+29) AGCRAAAGCAGGGTGACAAAGACATAATAATAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 604 - BM18_NS,1,873,39:(21+18) AGCRAAAGCAGGGTGACAAAGAACACCCTTGTTTCTACT ) SEQ ID NO: 605 - BM18_NS,1,869,43:(21+22) AGCRAAAGCAGGGTGACAAAGAAAAAACACCCTTGTTTCTACT ) SEQ ID NO: 606 - BM18_NS,1,837,73:(19+54) AGCRAAAGCAGGGTGACAAAAGAACTTTCTCGTTTCAGCTTATTTAATAATAAA AAACACCCTTGTTTCTACT Attorney Docket No.11676-003WO1 ) SEQ ID NO: 607 - BM18_NS,1,875,33:(17+16) AGCRAAAGCAGGGTGACCACCCTTGTTTCTACT ) SEQ ID NO: 608 - BM18_M,1,1006,69:(47+22) AGCRAAAGCAGGTAGATGTTGAAAGATGAGTCTTCTAACCGAGGTCGAAAAAA CTACCTTGTTTCTACT ) SEQ ID NO: 609 - BM18_M,1,1010,45:(27+18) AGCRAAAGCAGGTAGATGTTGAAAGATAACTACCTTGTTTCTACT ) SEQ ID NO: 610 - BM18_M,1,1000,54:(26+28) AGCRAAAGCAGGTAGATGTTGAAAGATGGAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 611 - BM18_M,1,1002,43:(17+26) AGCRAAAGCAGGTAGATGAGTAAAAAACTACCTTGTTTCTACT ) SEQ ID NO: 612 - BM18_NA,1,1429,56:(27+29) AGCRAAAGCAGGAGTTTAAATGAATCCGTTTGTTCAAAAAACTCCTTGTTTCTA CT ) SEQ ID NO: 613 - BM18_NA,1,1438,36:(16+20) AGCRAAAGCAGGAGTTAAAAACTCCTTGTTTCTACT ) SEQ ID NO: 614 - BM18_NP,1,1548,69:(51+18) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAATCATGGCGAA TACCCTTGTTTCTACT ) SEQ ID NO: 615 - BM18_NP,1,1541,64:(39+25) AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAGAAAAATACCC TTGTTTCTACT ) SEQ ID NO: 616 - BM18_NP,1,1547,55:(36+19) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGGTAGATAATCACTCACTGAGTGACAAATACCCTTGTTTCTAC T ) SEQ ID NO: 617 - BM18_NP,1,1545,42:(21+21) AGCRAAAGCAGGGTAGATAATAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 618 - BM18_NP,1,1550,34:(18+16) AGCRAAAGCAGGGTAGATTACCCTTGTTTCTACT ) SEQ ID NO: 619 - BM18_NP,1,1542,42:(18+24) AGCRAAAGCAGGGTAGATAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 620 - BM18_NP,1,1537,47:(18+29) AGCRAAAGCAGGGTAGATAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 621 - BM18_NP,1,1535,49:(18+31) AGCRAAAGCAGGGTAGATACAATTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 622 - BM18_NP,1,1539,43:(16+27) AGCRAAAGCAGGGTAGTTAAAGAAAAATACCCTTGTTTCTACT ) SEQ ID NO: 623 - BM18_PA,1,2208,57:(31+26) AGCRAAAGCAGGTACTGATTCAAAATGGAAGGTCCAAAAAAGTACCTTGTTTCT ACT ) SEQ ID NO: 624 - BM18_PA,1,2216,39:(21+18) AGCRAAAGCAGGTACTGATTCAAGTACCTTGTTTCTACT ) SEQ ID NO: 625 - BM18_PA,1,2213,41:(20+21) AGCRAAAGCAGGTACTGATTAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 626 - BM18_PA,1,2217,34:(17+17) AGCRAAAGCAGGTACTGAGTACCTTGTTTCTACT Attorney Docket No.11676-003WO1) SEQ ID NO: 627 - BM18_PA,1,2213,37:(16+21) AGCRAAAGCAGGTACTAAAAAGTACCTTGTTTCTACT ) SEQ ID NO: 628 - BM18_PB2,1,2323,48:(29+19) AGCRAAAGCAGGTCAATTATATTCAATATAAACGACCTTGTTTCTACT ) SEQ ID NO: 629 - BM18_PB2,1,2306,61:(25+36) AGCRAAAGCAGGTCAATTATATTCAAGTGTCGAATAGTTTAAAAACGACCTTGT TTCTACT ) SEQ ID NO: 630 - BM18_PB2,1,2314,48:(20+28) AGCRAAAGCAGGTCAATTATATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 631 - BM18_PB2,1,2326,34:(18+16) AGCRAAAGCAGGTCAATTCGACCTTGTTTCTACT ) SEQ ID NO: 632 - BM18_PB2,1,2293,67:(18+49) AGCRAAAGCAGGTCAATTATGGCCATCAATTAGTGTCGAATAGTTTAAAAACGA CCTTGTTTCTACT ) SEQ ID NO: 633 - BM18_PB2,1,2325,34:(17+17) AGCRAAAGCAGGTCAATACGACCTTGTTTCTACT ) SEQ ID NO: 634 - BM18_PB2,1,2308,51:(17+34) AGCRAAAGCAGGTCAATTGTCGAATAGTTTAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 635 - BM18_PB2,1,2320,38:(16+22) AGCRAAAGCAGGTCAATAAAAACGACCTTGTTTCTACT ) SEQ ID NO: 636 - BM18_PB1,1,2314,73:(45+28) AGCRAAAGCAGGCAAACCATTTGAATGGATGTCAATCCGACTTTACTTCATGAA AAAATGCCTTGTTTCTACT ) SEQ ID NO: 637 - BM18_PB1,1,2323,49:(30+19) Attorney Docket No.11676-003WO1 AGCRAAAGCAGGCAAACCATTTGAATGGATAAAATGCCTTGTTTCTACT 144) SEQ ID NO: 638 - BM18_PB1,1,2321,47:(26+21) AGCRAAAGCAGGCAAACCATTTGAATAAAAAATGCCTTGTTTCTACT 145) SEQ ID NO: 639 - BM18_PB1,1,2320,41:(19+22) AGCRAAAGCAGGCAAACCAGAAAAAATGCCTTGTTTCTACT 146) SEQ ID NO: 640 - BM18_PB1,1,2325,34:(17+17) AGCRAAAGCAGGCAAACAATGCCTTGTTTCTACT 147) SEQ ID NO: 641 - BM18_PB1,1,2317,42:(17+25) AGCRAAAGCAGGCAAACCATGAAAAAATGCCTTGTTTCTACT Example 6: Python script for sliding window analysis #Influenza virus RNA polymerase simulation script that searches for t-loops and checks up/down stream for intermol bp #Uses Python 3.8, biopython, openpyxl, and Vienna RNA 2.47; side packages were installed with Anaconda3 #By AJ te Velthuis, Sept 2020 import sys sys.path.append("/users/USER/opt/anaconda3/lib/python3.8/sit e-packages") ##input sequence. Paste sequence between quotation marks below. RNA = "PASTE SEQUENCE HERE" Name ="Template" ##output bubbles in txt file f= open("deltaGvalues.txt","w+") ##specify polymerase properties Footprint = 20 ##specify NP footprint NP = 24 Attorney Docket No.11676-003WO1 TloopDuplex = 48 Duplex = int(TloopDuplex / 2) ##specify window and other comparisons Uloop = "&" #Use & for co-fold to compute long-range interactions between upstream and downstream sequences. Swindow = 1 #size of sliding window ########################################### ##invert input sequence to start at 3' end NegRNA = RNA[::-1] Length = len(NegRNA) ########################################## ##polymerase bubble properties Bubble = Footprint + Duplex ##iteration start point of simulation; start at nt 2 otherwise downstream sequence is empty for co-fold i = 1 ##end bubble sequence and add 1, because sequence count starts at 0 End = int((Length - Footprint + 1) / Swindow) ##find polymerase bubble sequence; allow for small 3' part to emerge, but ##then cap how long the emerging sequence can be by assuming that every 24 nt will be bound by NP ##unclear if NP binds in chunks or progressively. Assume that at least 24 nt are needed based on data from Ortin lab. ##stops 1 nt from end to avoid having no sequence in cofold for i in range(1, End-1): if i <= NP: Upstream = i Attorney Docket No.11676-003WO1 Downstream = 0 else: Upstream = NP Downstream = i-NP #find upstream and downstream sequence of the bubble for intermolecular folding check Ahead = NegRNA[Footprint+i:Footprint+NP+i] Aheadinv = Ahead[::-1] #currently only takes 1 nt of downstream as 0 gives an error in cofold. Down = NegRNA[Downstream:i] Downinv = Down[::-1] ##find the two duplex ends and invert them so they are 5' to 3' if i <= Duplex: Prime3 = NegRNA[0:Upstream] else: Prime3 = NegRNA[i-Duplex:i] Prime3inv = Prime3[::-1] if i <= End: Prime5 = NegRNA[Footprint+i:Bubble+i] else: Prime5 = NegRNA[Footprint+i:Length] Prime5inv = Prime5[::-1] #compute A/U content of nucleotides in active site. Assume window of 6 before and after active site. Various print options are inactivated, but can be used for checking if script works. ActiveSite = i + 16 #print("location of bubble is ", i+1) #print("3 prime end 3' to 5' is ", Prime3) #print("5 prime end 5' to 3' is ", Prime5inv) ActiveSiteSeqUp = NegRNA[ActiveSite-1:ActiveSite+4] Attorney Docket No.11676-003WO1 ActiveSiteSeqDown = NegRNA[ActiveSite-5:ActiveSite] #seq_up_list = list(ActiveSiteSeqUp) seq_up_list = list(ActiveSiteSeqDown) at_count_up = seq_up_list.count("a") + seq_up_list.count ("t") + seq_up_list.count("A") + seq_up_list.count ("T") + seq_up_list.count ("u") + seq_up_list.count ("U") at_frac_up = float(at_count_up)/5 total_at_up = 100 * at_frac_up ##saving the A/U content is inactivated below #print(total_at_up) #f.write("%f\n" % (total_at_up)) ##Vienna RNA package for RNA structure prediction import RNA Test = Prime3 + Uloop + Prime5 NegTest = Test[::-1] #Output = (">"+Name+"_polymerase_bubble_number_%d\n" % (i+1)) ##To write bubble sequence to .txt file #f.write(Output) #f.write(NegTest) #f.write("\r\n") #use duplex fold to compute t-loop from Vienna package because it ignores intermol bp duplex = RNA.duplexfold(Prime5inv, Prime3inv) #print("%s\n%s [%6.2f]" % (NegTest, duplex.structure, duplex.energy)) ##print("%6.2f" % (duplex.energy)) #use cofold from Vienna package to check for bp in sequence upstream and downstream of t-loop. Various options can be checked separately, including just upstream seq, just downstream seq, or both seq Other = Aheadinv + Uloop + Downinv #Other = Aheadinv Attorney Docket No.11676-003WO1 #Other = Downinv (ss, mfe_dimer) = RNA.cofold(Other) #print("%s\n%s [%6.2f]" % (Other, ss, mfe_dimer)) DDeltaG = duplex.energy - mfe_dimer ##compute DeltaDeltaG ##check if deltaG of t-loop is lower than deltaG of other structures if duplex.energy >= mfe_dimer: DeltaG = mfe_dimer * -1 #elif duplex.energy >= 0: #DeltaG = 0 else: #DeltaG = duplex.energy DeltaG = duplex.energy #DeltaG = mfe_dimer #DeltaG = duplex.energy #print(DeltaG) #print(DDeltaG) #print(duplex.energy) #print("%s\n%s [ %6.2f ]" % (NegTest, ss, mfe)) ##to write deltaG values to .txt file. Various options are available depending on what is being analyzed. f.write("%f\n" % (duplex.energy)) #f.write("%f\n" % (DeltaG)) #f.write("%f\n" % (mfe_dimer)) #print(NegTest) #print("-----") i =+ Swindow #################################################### ##close .txt file that deltaG values were written to Attorney Docket No.11676-003WO1 f.close() print ("Done %s" % (Name)) It will be apparent to those skilled in the art that various modifications and variations can be made in the present disclosure without departing from the scope or spirit of the invention. Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the methods disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Attorney Docket No.11676-003WO1 TABLES Table 1. Sequences of mvRNA templates used. Attorney Docket No.11676-003WO1 Table 2. Cloned PB1 WSN mvRNAs. Attorney Docket No.11676-003WO1 Table 3. Cloned mvRNAs based on t-loop analysis.